CA3046915A1 - Use of rock inhibitors for promoting sinonasal epithelial cell repair - Google Patents
Use of rock inhibitors for promoting sinonasal epithelial cell repair Download PDFInfo
- Publication number
- CA3046915A1 CA3046915A1 CA3046915A CA3046915A CA3046915A1 CA 3046915 A1 CA3046915 A1 CA 3046915A1 CA 3046915 A CA3046915 A CA 3046915A CA 3046915 A CA3046915 A CA 3046915A CA 3046915 A1 CA3046915 A1 CA 3046915A1
- Authority
- CA
- Canada
- Prior art keywords
- rho
- rock
- signaling pathway
- pathway inhibitor
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 130
- 230000008439 repair process Effects 0.000 title claims abstract description 67
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 239000011435 rock Substances 0.000 title abstract 4
- 230000019491 signal transduction Effects 0.000 claims abstract description 89
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims abstract description 60
- 201000009890 sinusitis Diseases 0.000 claims abstract description 24
- 239000013543 active substance Substances 0.000 claims abstract description 15
- 150000003431 steroids Chemical class 0.000 claims abstract description 15
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 7
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 claims description 90
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 23
- 238000013129 endoscopic sinus surgery Methods 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 17
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 claims description 16
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 13
- ZAVGJDAFCZAWSZ-UHFFFAOYSA-N hydroxyfasudil Chemical compound C1=CC=C2C(O)=NC=CC2=C1S(=O)(=O)N1CCCNCC1 ZAVGJDAFCZAWSZ-UHFFFAOYSA-N 0.000 claims description 12
- 208000035143 Bacterial infection Diseases 0.000 claims description 11
- 208000000592 Nasal Polyps Diseases 0.000 claims description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 11
- 102000053038 human ROCK1 Human genes 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 10
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102000053046 human ROCK2 Human genes 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- AWDORCFLUJZUQS-ZDUSSCGKSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-ZDUSSCGKSA-N 0.000 claims description 6
- WDTFYYZHMRBVHK-LJQANCHMSA-N 1-[(1s)-2-hydroxy-1-phenylethyl]-3-(4-pyridin-4-ylphenyl)urea Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(=O)NC(C=C1)=CC=C1C1=CC=NC=C1 WDTFYYZHMRBVHK-LJQANCHMSA-N 0.000 claims description 6
- GDVRVPIXWXOKQO-UHFFFAOYSA-N 1-[(3-hydroxyphenyl)methyl]-3-(4-pyridin-4-yl-1,3-thiazol-2-yl)urea Chemical compound OC1=CC=CC(CNC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 GDVRVPIXWXOKQO-UHFFFAOYSA-N 0.000 claims description 6
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 claims description 6
- HEAIGWIZTYAQTC-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-(1h-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxamide Chemical compound N1C(=O)NC(C)=C(C(=O)NC=2C=C3C=NNC3=CC=2)C1C1=CC=C(F)C=C1 HEAIGWIZTYAQTC-UHFFFAOYSA-N 0.000 claims description 6
- JTVBXQAYBIJXRP-SNVBAGLBSA-N 4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 JTVBXQAYBIJXRP-SNVBAGLBSA-N 0.000 claims description 6
- DWTNLZZEPSCAIH-VOMCLLRMSA-N C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC2=C1C=CN2 Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC2=C1C=CN2 DWTNLZZEPSCAIH-VOMCLLRMSA-N 0.000 claims description 6
- CMKMGFAUKPAOMG-AWEZNQCLSA-N Glycyl-H-1152 Chemical compound C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 CMKMGFAUKPAOMG-AWEZNQCLSA-N 0.000 claims description 6
- OLIIUAHHAZEXEX-UHFFFAOYSA-N N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide Chemical compound C1C(=O)NC(C)=C(C(=O)NC=2C(=CC=3NN=CC=3C=2)F)C1C1=CC=C(C(F)(F)F)C=C1 OLIIUAHHAZEXEX-UHFFFAOYSA-N 0.000 claims description 6
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims description 6
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 6
- PHWHNHYZZNJPLB-QMMMGPOBSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3s)-3-aminopyrrolidin-1-yl]methanone Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@H](N)C1 PHWHNHYZZNJPLB-QMMMGPOBSA-N 0.000 claims description 6
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 claims description 6
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical group C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 6
- DQNMDJGZWFZNHS-UHFFFAOYSA-N n-(4,5-dihydrobenzo[e][1,3]benzothiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NC(S1)=NC2=C1CCC1=CC=CC=C21 DQNMDJGZWFZNHS-UHFFFAOYSA-N 0.000 claims description 6
- XUIUXXQVHPEQNM-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)phenyl]methanamine Chemical compound FC1=CC=CC=C1CNCC1=CC=C(C=2C=3C=CNC=3N=CC=2)C=C1 XUIUXXQVHPEQNM-UHFFFAOYSA-N 0.000 claims description 6
- OQWZIAVXCYIZNN-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethoxy]-4-(1h-pyrazol-4-yl)phenyl]-2,3-dihydro-1,4-benzodioxine-3-carboxamide Chemical compound C=1C=C(NC(=O)C2OC3=CC=CC=C3OC2)C(OCCN(C)C)=CC=1C=1C=NNC=1 OQWZIAVXCYIZNN-UHFFFAOYSA-N 0.000 claims description 6
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 claims description 6
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 claims description 6
- 229950009210 netarsudil Drugs 0.000 claims description 6
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 claims description 6
- 229950007455 ripasudil Drugs 0.000 claims description 6
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims description 6
- NRSGWEVTVGZDFC-UHFFFAOYSA-N 6-chloro-4-n-[3,5-difluoro-4-[(3-methyl-1h-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine Chemical compound C=12C(C)=CNC2=NC=CC=1OC(C(=C1)F)=C(F)C=C1NC1=CC(Cl)=NC(N)=N1 NRSGWEVTVGZDFC-UHFFFAOYSA-N 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 33
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 230000008929 regeneration Effects 0.000 abstract description 6
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 230000002950 deficient Effects 0.000 abstract description 5
- 210000003695 paranasal sinus Anatomy 0.000 abstract description 5
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 64
- 208000027418 Wounds and injury Diseases 0.000 description 37
- 238000011282 treatment Methods 0.000 description 31
- 206010052428 Wound Diseases 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 206010020751 Hypersensitivity Diseases 0.000 description 22
- 208000026935 allergic disease Diseases 0.000 description 22
- 230000007815 allergy Effects 0.000 description 22
- 210000001243 pseudopodia Anatomy 0.000 description 21
- 241000191967 Staphylococcus aureus Species 0.000 description 14
- 230000006378 damage Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000010152 Bonferroni least significant difference Methods 0.000 description 9
- 230000004890 epithelial barrier function Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000002939 deleterious effect Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 8
- 229960001262 tramazoline Drugs 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000004082 barrier epithelial cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002262 irrigation Effects 0.000 description 7
- 238000003973 irrigation Methods 0.000 description 7
- 210000005265 lung cell Anatomy 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 6
- 210000001552 airway epithelial cell Anatomy 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- -1 from camelids) Proteins 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 101150111584 RHOA gene Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 230000037314 wound repair Effects 0.000 description 4
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010009711 Phalloidine Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000576901 Homo sapiens Serine/threonine-protein kinase MRCK alpha Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100025352 Serine/threonine-protein kinase MRCK alpha Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000003518 stress fiber Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 description 1
- 101710172419 5-azacytidine-induced protein 2 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000025678 Ciliary Motility disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010037663 Cortactin Proteins 0.000 description 1
- 102000010958 Cortactin Human genes 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 description 1
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000002137 Functioning pituitary adenoma Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710147195 Hemolysin A Proteins 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 101000614627 Homo sapiens Keratin, type I cytoskeletal 13 Proteins 0.000 description 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101150037996 KRT5 gene Proteins 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 102100022496 Mucin-5AC Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 108010022461 Pseudomonas aeruginosa pseudolysin Proteins 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100031363 Rhophilin-1 Human genes 0.000 description 1
- 101710094429 Rhophilin-1 Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000004783 epithelial tight junction Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 208000038004 exacerbated respiratory disease Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000013695 functioning pituitary gland adenoma Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 238000013134 sino-nasal outcome test Methods 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Novel methods and uses for promoting sinonasal epithelial cell repair in a subject are described. These methods and uses are based on the administration of Rho/ROCK signaling pathway inhibitors, such as ROCK inhibitors. Subjects that may benefit from these methods and uses are those suffering from diseases/conditions associated with impaired nasal and paranasal sinus mucosa integrity and/or defective sinonasal epithelial repair and regeneration, such as rhinosinusitis (e.g., chronic rhinosinusitis, CRS). The Rho/ROCK signaling pathway inhibitors may be used alone or in combination with other active agents, such as steroids and/or antibiotics.
Description
G16612.00005 USE OF ROCK INHIBITORS FOR PROMOTING SINONASAL EPITHELIAL CELL
REPAIR
TECHNICAL FIELD
The present disclosure generally relates to sinonasal epithelial cell repair, and more specifically to the treatment of conditions associated with defective sinonasal epithelial repair and regeneration such as chronic rhinosinusitis (CRS).
BACKGROUND ART
Chronic rhinosinusitis (CRS) is defined as a persistent inflammation of sinonasal mucosa, lasting for more than 12 weeks'. This disease affects 4.5 to 12% of the population in North American and European Countries2, and seriously compromises the quality of life (QoL) indices in affected individuals43. Patients with the CRS with nasal polyps (CRSwNP) phenotype have significantly greater impairment of disease-specific QoL than those with CRS without NP4.
In addition, 40% of patients will present endoscopic recurrence within 6 months after endoscopic sinus surgery (ESS) , with 20% requiring revision surgery within 5 years .
Despite the high personal, social and economic impact of CRSwNP, its physiopathology is still poorly understood. Increasing experimental evidence suggests that the epithelial barrier plays an important role in the disease process74. In addition to its role as a physical barrier to pathogens and irritants, epithelial cells are also responsible for initiating and coordinating defensive responses. Upon stimulation, they secrete several cytokines, such as IL-8, IL-33, 1L-25 and thymic stromal lymphopoietin (TSLP), which serve to initiate multiple signaling pathways. In light of this, it is currently believed that reduced barrier function following damage to the epithelial lining is a potent contributor to type 2 immunity'. Adequate epithelial repair after injury is essential to restore epithelial barrier integrity and to avoid the subepithelial penetration of inhalant particles and deep tissue colonization with pathogenic bacterial , thereby perpetuating inflammation and facilitating subsequent infection.
Recent studies have suggested that epithelial repair and regeneration are altered in CRSwNP. Yu etal. has shown impaired basal cell growth and proliferation'', as well as epithelial remodeling (hyperplasia and squamous metaplasia)12 in CRSwNP.
There is thus a need for the development of novel approaches for promoting repair of the sinonasal mucosa for the treatment of conditions associated with defective sinonasal epithelial repair and regeneration such as CRS.
The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.
G16612.00005
REPAIR
TECHNICAL FIELD
The present disclosure generally relates to sinonasal epithelial cell repair, and more specifically to the treatment of conditions associated with defective sinonasal epithelial repair and regeneration such as chronic rhinosinusitis (CRS).
BACKGROUND ART
Chronic rhinosinusitis (CRS) is defined as a persistent inflammation of sinonasal mucosa, lasting for more than 12 weeks'. This disease affects 4.5 to 12% of the population in North American and European Countries2, and seriously compromises the quality of life (QoL) indices in affected individuals43. Patients with the CRS with nasal polyps (CRSwNP) phenotype have significantly greater impairment of disease-specific QoL than those with CRS without NP4.
In addition, 40% of patients will present endoscopic recurrence within 6 months after endoscopic sinus surgery (ESS) , with 20% requiring revision surgery within 5 years .
Despite the high personal, social and economic impact of CRSwNP, its physiopathology is still poorly understood. Increasing experimental evidence suggests that the epithelial barrier plays an important role in the disease process74. In addition to its role as a physical barrier to pathogens and irritants, epithelial cells are also responsible for initiating and coordinating defensive responses. Upon stimulation, they secrete several cytokines, such as IL-8, IL-33, 1L-25 and thymic stromal lymphopoietin (TSLP), which serve to initiate multiple signaling pathways. In light of this, it is currently believed that reduced barrier function following damage to the epithelial lining is a potent contributor to type 2 immunity'. Adequate epithelial repair after injury is essential to restore epithelial barrier integrity and to avoid the subepithelial penetration of inhalant particles and deep tissue colonization with pathogenic bacterial , thereby perpetuating inflammation and facilitating subsequent infection.
Recent studies have suggested that epithelial repair and regeneration are altered in CRSwNP. Yu etal. has shown impaired basal cell growth and proliferation'', as well as epithelial remodeling (hyperplasia and squamous metaplasia)12 in CRSwNP.
There is thus a need for the development of novel approaches for promoting repair of the sinonasal mucosa for the treatment of conditions associated with defective sinonasal epithelial repair and regeneration such as CRS.
The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.
G16612.00005
2 SUMMARY OF THE INVENTION
The present disclosure provides the following items 1 to 55:
1. A method for promoting sinonasal epithelial cell repair in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK
signaling pathway inhibitor.
2. The method of item 1, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
The present disclosure provides the following items 1 to 55:
1. A method for promoting sinonasal epithelial cell repair in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK
signaling pathway inhibitor.
2. The method of item 1, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
3. The method of item 2, wherein the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 and/or ROCK2 and blocks its activity.
4. The method of item 2, wherein the ROCK inhibitor is an antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 and/or human ROCK2.
5. The method of item 2, wherein the ROCK inhibitor is Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S 7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
6. The method of item 5, wherein the ROCK inhibitor is Y-27632 or a pharmaceutically acceptable salt thereof.
7. The method of item 6, wherein the ROCK inhibitor is a dihydrochloride salt of Y-27632.
8. The method of any one of items 1 to 7, wherein the subject suffers from rhinosinusitis.
9. The method of item 8, wherein the subject suffers from chronic rhinosinusitis (CRS).
10. The method of item 9, wherein the subject suffers from CRS with nasal polyps (CRSwNP).
11. The method of any one of items 8 to 10, wherein the subject underwent endoscopic sinus surgery (ESS) prior to said administering.
12. The method of any one of items 8 to 11, wherein the rhinosinusitis is associated with a bacterial infection.
13. The method of item 12, wherein the bacterial infection comprises Staphylococcus aureus infection.
14. The method of any one of items 1 to 13, wherein the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition with at least one pharmaceutically acceptable carrier or excipient.
15. The method of any one of items 1 to 14, wherein the Rho/ROCK signaling pathway inhibitor is administered intranasally.
16. The method of item 15, wherein the Rho/ROCK signaling pathway inhibitor is coated on a nasal or sinus implant.
17. The method of any one of items 1 to 16, wherein the Rho/ROCK signaling pathway inhibitor is administered in combination with at least one additional active agent.
G16612.00005
G16612.00005
18. The method of item 17, wherein the at least one additional active agent comprises a steroid and/or an antibiotic.
19. Use of a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
20. Use of a Rho/ROCK signaling pathway inhibitor for the manufacture of a medicament for promoting sinonasal epithelial cell repair in a subject
21. The use of item 19 or 20, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
22. The use of item 21, wherein the ROCK inhibitor is an antibody or an antigen-binding .. fragment thereof that binds to ROCK1 and/or ROCK2 and blocks its activity.
23. The use of item 21, wherein the ROCK inhibitor is an antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 and/or human ROCK2.
24. The use of item 21, wherein the ROCK inhibitor is Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, .. AT13148, H1152, Glycyl-H1152, TO-S 7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
25. The use of item 24, wherein the ROCK inhibitor is Y-27632 or a pharmaceutically acceptable salt thereof.
26. The use of item 25, wherein the ROCK inhibitor is a dihydrochloride salt of Y-27632.
27. The use of any one of items 19 to 26, wherein the subject suffers from rhinosinusitis.
28. The use of item 27, wherein the subject suffers from chronic rhinosinusitis (CRS).
29. The use of item 28, wherein the subject suffers from CRS with nasal polyps (CRSwNP).
30. The use of any one of items 27 to 29, wherein the subject underwent endoscopic sinus .. surgery (ESS) prior to said use.
31. The use of any one of items 27 to 30, wherein the rhinosinusitis is associated with a bacterial infection.
32. The use of item 31, wherein the bacterial infection comprises Staphylococcus aureus infection.
33. The use of any one of items 19 to 32, wherein the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition with at least one pharmaceutically acceptable carrier or excipient.
34. The use of any one of items 19 to 33, wherein the Rho/ROCK signaling pathway inhibitor is for intranasal administration.
35. The use of item 34, wherein the Rho/ROCK signaling pathway inhibitor is coated on a nasal or sinus implant.
G16612.00005
G16612.00005
36. The use of any one of items 19 to 35, wherein the Rho/ROCK signaling pathway inhibitor is used in combination with at least one additional active agent.
37. The use of item 36, wherein the at least one additional active agent comprises a steroid and/or an antibiotic.
38. A Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
39. The Rho/ROCK signaling pathway inhibitor for use according to item 38, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
40. The Rho/ROCK signaling pathway inhibitor for use according to item 39, wherein the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 and/or ROCK2 and blocks its activity.
41. The Rho/ROCK signaling pathway inhibitor for use according to item 39, wherein the ROCK inhibitor is an antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 and/or human ROCK2.
42. The Rho/ROCK signaling pathway inhibitor for use according to item 39, wherein the ROCK inhibitor is Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S
7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
43. The Rho/ROCK signaling pathway inhibitor for use according to item 42, wherein the ROCK inhibitor is Y-27632 or a pharmaceutically acceptable salt thereof.
44. The Rho/ROCK signaling pathway inhibitor for use according to item 43, wherein the ROCK inhibitor is a dihydrochloride salt of Y-27632.
45. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 38 to 44, wherein the subject suffers from rhinosinusitis.
46. The Rho/ROCK signaling pathway inhibitor for use according to item 45, wherein the subject suffers from chronic rhinosinusitis (CRS).
47. The Rho/ROCK signaling pathway inhibitor for use according to item 46, wherein the subject suffers from CRS with nasal polyps (CRSwNP).
48. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 38 to 47, wherein the subject underwent endoscopic sinus surgery (ESS) prior to said use.
49. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 45 to 48, wherein the rhinosinusitis is associated with a bacterial infection.
50. The Rho/ROCK signaling pathway inhibitor for use according to item 49, wherein the bacterial infection comprises Staphylococcus aureus infection.
G16612.00005
G16612.00005
51. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 38 to 50, wherein the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition with at least one pharmaceutically acceptable carrier or excipient.
52. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 38 to 5 51, wherein the Rho/ROCK signaling pathway inhibitor is for intranasal administration.
53. The Rho/ROCK signaling pathway inhibitor for use according to item 52, wherein the Rho/ROCK signaling pathway inhibitor is coated on a nasal or sinus implant.
54. The Rho/ROCK signaling pathway inhibitor for use according to any one of items 38 to 53, wherein the Rho/ROCK signaling pathway inhibitor is used in combination with at least one additional active agent.
55. The Rho/ROCK signaling pathway inhibitor for use according to item 54, wherein the at least one additional active agent comprises a steroid and/or an antibiotic.
Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.
BRIEF DESCRIPTION OF DRAWINGS
In the appended drawings:
FIGs. 1A and 1B show that nasal airway epithelial repair rate is poorest in CRSwNP
than in control epithelia under baseline conditions. Cell monolayers obtained from pNECs from control subjects or CRSwNP patients were mechanically injured and epithelial repair rates were measured over a 6h-period. FIG. 1A: Representative pictures of injured epithelia from a control subject (left) and a CRSwNP patient (right) were obtained from inverted microscope (4x). Pictures were taken immediately after the injury has been made (Oh, above) and after a 6h- period of repair (6h, below). Wounds have been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. FIG. 1B: Quantitative analysis of epithelial repair rate, from 15 patients in each group. Samples were derived at the same time and pNECs cultures were processed in parallel in order to compare control and CRSwNP repair rates. Differences between control and CRSwNP repair rates were assessed by one-way ANOVA
followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*).;
FIGs. 2A and 2B show that exposure to S. aureus exoproducts decreases nasal epithelial repair rates. pNECs monolayers obtained from control subjects (FIG.
2A) and CRSwNP
patients (FIG. 2B) were mechanically injured and treated with LB (left), SA
0.25% (middle) and SA 0.5% (right), and epithelial repair rates were measured over a 6h-period.
Upper panels:
Representative pictures of injured epithelia from a control subject (FIG. 2A) and a CRSwNP
patient (FIG. 2B) were obtained with an inverted microscope (4x). Pictures were taken immediately after injury (Oh, above) and after a 6h-period of repair (6h, below). Wounds have G16612.00005 been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. Quantitative analysis of epithelial repair rates, from 11 control subjects (FIG.
2A) and 12 CRSwNP patients (FIG. 2B), in control condition (LB) and after exposure to SA
exoproducts at 0.25% (v/v) and 0.5% (v/v). The values obtained in each condition were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).*;
FIGs. 3A and 3B show lamellipodial dynamics of control and CRSwNP nasal epithelial cells are affected by exposure to S. aureus exoproducts. pNECs from control subjects (FIG. 3A) or CRSwNP patients (FIG. 3B) were treated with LB at the beginning of the experiment and imaged every minute for 2 hours. Then, S. aureus exoproducts (SA) were added and recording were pursued for the next 4h (SA(0-2h) and SA(2-4h)). Upper panels:
representative kymographs taken from time-lapse series of pNECs from a control subject (FIG. 3A) and a patient with CRSwNP (FIG. 3B). Kymographs depict variations in lamellipodial activity along a one-pixel-wide line drawn perpendicularly to the cell membrane in sequential phase-contrast images. Ascending contours show lamellipodial protrusion, whereas descending contours show lamellipodial retraction. Lower panels: Quantitative analysis of lamellipodial dynamics in pNECs from control subjects (FIG. 3A) and CRSwNP patients (FIG. 3B). Length and velocity of protrusions were calculated from the slopes traced on the leading edge of cells on 14-15 kymographs (each kymograph was taken from one cell) from 3 controls (FIG. 3A) and 3 CRSwNP
patients (FIG. 3B).
Means were calculated for 3 distinct periods, t=Oh to t=2h (LB, control condition), t=2h to t=4h (SA
(0-2h)) and t=4h to t=6h (SA (2-4h)). Differences between groups (LB, SA (0-2h) and SA (2-4h)) were assessed by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).
FIGs. 4A and 4B show that exposure to S. aureus exoproducts affects cytoskeleton organization of nasal epithelia from control subjects and CRSwNP patients.
FIG. 4A:
Representative confocal microscopy images of nasal epithelia from control subjects and CRSwNP patients mechanically injured and treated with either LB (control condition) or S. aureus exoproducts (SA, 0.5%) for 4h. Cells were stained for microtubules (with anti-13-tubulin antibody, upper panels) and actin stress fibers (phalloidin staining, middle panels), and nuclei were labeled with DAPI. Cells were visualized using a Leica TCS SP5 confocal microscope (magnification x63).
Merged images are shown on lower panels. White asterisks indicate cell protrusions at the leading edge of the wounds. Insets are shown to emphasize the cell shapes. Scale bars represent 25 pm.
If necessary, images were rotated to place the wounds at the top of each photograph. FIG. 4B:
Results of the lamellipodial cell quantification. The percentages of cells with lamellipodia (dark grey), with ambiguous morphology (light grey) or without lamellipodia (white) at the wound edge were counted on immunofluorescences images of nasal epithelia from control subjects (Control) and CRSwNP patients (CRS) after mechanical injury and treatment with either LB
or SA
G16612.00005 exoproducts (SA 0.5%). Left panel shows the repartition (in c/o) of cells according the 3 categories.
Values are means SEM from n=4 independent experiments (at least 80 cells per condition were classified). Insert (right) shows the results of the statistical analysis.
Differences between groups were assessed by one-way ANOVA followed by Bonferroni post-hoc tests.
Statistical differences are indicated as follows: p<0.05 (*) and p<0.001 (***).
FIGs. 5A and 5B show that ROCK inhibitor Y-27632 prevented the deleterious effect of S. aureus on epithelial repair rates of CRSwNP nasal epithelial cells. pNECs monolayers from CRSwNP patients were injured, treated with LB + vehicle (water), SA (0.25%) +
vehicle (water) and SA (0.25%) + Y-27632, SA (0.5%) + vehicle (water) or SA (0.5%) + Y-27632, and then .. epithelial repair rates were calculated over a 6h period. FIG. 5A:
Representative pictures of injured epithelia from a CRSwNP patient were obtained in the different conditions and taken at Oh (above) and 6h (below) after injury with an inverted microscope (4x).
Wounds have been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. FIG. 5B: Quantitative analysis of epithelial repair rates from 15 CRSwNP patients.
The values obtained from each condition within the same group were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).
FIGs. 6A and 6B show that ROCK inhibition attenuates the negative impact of S.
aureus exoproducts on lamellipodial dynamics of nasal epithelial cells from CRSwNP.
pNECs monolayers from CRSwNP patients were treated with LB + vehicle (water) at the beginning of the experiment and imaged every minute for 2h. Then, a combination of 0.5% of SA
exoproducts and 5pM of the ROCK inhibitor Y-27632 (SA + Y) was added, and recording were pursued for the next 4h. FIG. 6A: Representative kymograph taken from phase-contrast time-lapse series of pNECs from a patient with CRSwNP (right). FIG. 6B: Quantitative analysis of lamellipodial dynamics.
Length (upper panels) and velocity (lower panels) of protrusions (left panels) and retractions (right panels) were calculated from the slopes traced on the leading edge of cells on 11 kymographs (each kymograph was taken from one cell) from 3 independent experiments (i.e.
3 CRSwNP
patients) (N=3 patients, n=11 cells). Means were calculated for 3 distinct periods, t=Oh to t=2h (LB, control condition), t=2h to t=4h (SA +Y (0-2h)) and t=4h to t=6h (SA + Y
(2-4h)). Differences between groups were assessed by repeated measures ANOVA followed by Bonferroni post-hoc tests. All comparisons were established as non-significant following statistical analysis (p>0.05).
FIGs. 7A and 7B show that ROCK inhibition protects cytoskeleton disorganization of nasal epithelial cells from CRSwNP due to S. aureus exoproduct exposure. FIG.
7A:
Representative confocal microscopy images of nasal epithelia from CRSwNP
patients mechanically injured and treated with either LB + vehicle (water, control condition), SA
exoproducts (SA 0.5%) + vehicle (water) or SA exoproducts and Y-27632 (SA 0.5%
+ Y-27632 5pM) for 4h. Cells were stained for microtubules (with an anti-8-tubu)in antibody, upper panels) G16612.00005 and actin stress fibers (phalloidin staining, middle panels), and nuclei were labeled with DAPI.
Cells were visualized using a Leica TCS SP5 confocal microscope (magnification x63). Merged images are shown on lower panels. White asterisks indicate protrusions at the leading edge of the wounds. Insets are shown to emphasize the cell shapes. Scale bars represent 25 pm. If necessary, images were rotated to place the wounds at the top of each photograph. FIG. 7B:
Results of lamellipodial cell quantification. The percentages of cells with lamellipodia (dark grey), with ambiguous morphology (light grey) or without lamellipodia (white) at the wound edge were counted on immunofluorescences images of nasal epithelia from control subjects (Control) and CRSwNP patients (CRS) after mechanical injury and treatment with either LB +
vehicle (LB), SA
exoproducts (SA 0.5%) + vehicle (SA) or SA exoproducts (SA 0.5%) + Y-27632 (Y-27632 5 pM) (SA+Y). Left panel shows the repartition (in %) of cells according the 3 categories. Values are means SEM from n=4 independent experiments (at least 110 cells per condition were classified).
Insert (right) shows the results of the statistical analysis. Differences between groups were assessed by one-way ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as follows: p<0.05 (*) and p<0.001 (***).
FIG. 8 shows a kymograph taken from a phase-contrast time-lapse series showing local protrusion¨retraction cycles. Dotted arrows indicate protrusion and retraction phases. Protrusion and retraction length and velocity were calculated using Multiple Kymograph and tsp050706 plugin for ImageJ by tracing a segmented line along the edge of lamellipodia on kymographs.
FIGs. 9A and 9B show that heat-inactivation of SA exoproducts prevents the negative impact of SA exoproducts on the repair rates of CRSwNP nasal epithelia. pNECs monolayers obtained from pNECs from CRSwNP patients were mechanically injured and treated with LB (left), SA exoproducts 0.5% (SA - middle) or heat-inactivated SA exoproducts 0.5%
(SArnactive - right) and epithelial repair rates were measured over a 6h-period. Heat inactivation was performed by heating SA exoproducts at 95 C for 15 minutes. FIG. 9A: Representative pictures were taken immediately after injury (Oh, upper panels) and after 6h of repair (6h, lower panels) with an inverted microscope (4x). Wounds have been brightened on the pictures and dotted lines have been drawn at the wound edges for a better visualization. FIG. 9B:
Quantitative analysis of epithelial repair rates, from 3 patients. The values obtained from each situation within the same group were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests.
Statistical differences are indicated as p<0.001 (***) or non-significant (NS).
FIG. 10 depicts the lamellipodia quantification method used in the studies described herein. Example of cells classified according to the categories with or without lamellipodia as well as with ambiguous morphology. Percentages of cells in each category were then calculated.
FIGs. 11A-11C show the structure of representative ROCK inhibitors.
FIGs. 12A and 12B depict the amino acid sequences of human ROCK1 (UniProtKB -Q13464, SEQ ID NO:2) and ROCK2 (UniProtKB -075116, SEQ ID NO:4), respectively.
G16612.00005 FIGs. 12C and 12D depict the nucleotide sequences of the gene encoding human ROCK1 (FIG. 12C, SEQ ID NO:1) and human ROCK2 (FIG. 12D, SEQ ID NO:3), respectively.
DISCLOSURE OF INVENTION
The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All subsets of values within the ranges are also incorporated into the specification as if they were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Herein, the term "about" has its ordinary meaning. The term "about" is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10%
or 5% of the recited values (or range of values).
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In the studies described herein, the present inventors have shown that there is an intrinsic defect in epithelial repair in CRSwNP patients, and that SA
exoproduct exposure alters epithelial repair of normal cells and accentuate the abnormal repair in CRSwNP
cells.
Furthermore, the studies described herein demonstrate that the effect of SA on cell protrusion is more sustained over time in pNECs cultures from CRSwNP patients. The present inventors have also provided evidence that targeting the Rho/Rho kinase signaling pathway constitutes a new strategy to counteract the negative effect of SA, as the deleterious effect of SA on repair rate and lamellipodia of CRSwNP pNECs cultures was prevented by Rho-associated protein kinase G16612.00005 (ROCK) inhibition using the representative ROCK inhibitor Y-27632. These results provide compelling evidence that Rho/ROCK signaling pathway inhibition may be useful for promoting sinonasal epithelial cell repair, and consequently for the treatment of diseases/conditions associated with impairment of nasal and paranasal sinus mucosa integrity and/or sinonasal 5 epithelial repair and regeneration, such as rhinosinusitis.
Accordingly, in a first aspect, the present disclosure provides a method for promoting sinonasal epithelial cell repair in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK signaling pathway inhibitor. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial 10 .. cell repair in a subject. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for the manufacture of a medicament for promoting sinonasal epithelial cell repair in a subject. The present disclosure also provides a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
In an embodiment, the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor. The term "ROCK inhibitor" as used herein refers to a peptide, a protein, a nucleic acid (antisense oligonucleotides, RNA interference agents such as siRNAs, shRNAs, miRNAs, ribozymes), a small molecule, an antibody or other agent that prevents or reduces expression of ROCK or inhibits ROCK activity, such as its kinase activity.
ROCK is a serine/threonine kinase belonging to the AGC family of protein kinases, which .. are structurally related to myotonic dystrophy kinase (DMPK) and myotonic dystrophy kinase-related CDC42-binding kinase (MRCK). ROCK is composed of an N-terminal catalytic domain, a central coiled-coil domain, and a C-terminal Pleckstrin homology (PH) domain interrupted by a Cysteine-rich region. ROCK requires both N- and C-terminal extension segments in addition to the core catalytic domain for its activity, which is conserved among the DMPK
subgroup. Rho activates ROCK by binding to the C-terminal portion of the coiled-coil. The amino acid sequences of human ROCK1 (UniProtKB - Q13464, SEQ ID NO:2) and ROCK2 (UniProtKB -075116, SEQ
ID NO:4) are disclosed in FIG. 12A and FIG. 12B, respectively, and the nucleotides sequences of the cDNAs encoding human ROCK1 and ROCK2 are disclosed in FIG. 12C (SEQ ID
NO:1) and FIG. 12D (SEQ ID NO:3), respectively.
In an embodiment, the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 (FIG. 12A) and/or ROCK2 (FIG. 12B) and blocks its activity, for example by blocking its binding to one of its ligand or substrate. The term "antibody or antigen-binding fragment thereof" as used herein refers to any type of antibody/antibody fragment including monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies, humanized antibodies, CDR-grafted antibodies, chimeric antibodies and antibody fragments so long as they exhibit the desired antigenic specificity/binding activity. Antibody fragments comprise a portion of a full-length antibody, generally an antigen G16612.00005 binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules (e.g., single-chain FV, scFV), single domain antibodies (e.g., from camelids), shark NAR single domain antibodies, and multispecific antibodies formed from antibody fragments. Antibody fragments can also refer to binding moieties comprising CDRs or antigen binding domains including, but not limited to, VH
regions (VH, anticalins, PepBodies, antibody-T-cell epitope fusions (Troybodies) or Peptibodies.
In other embodiments, the ROCK inhibitor is an antisense or RNA interference compound. Antisense or RNA interference compounds include, but are not limited to, antisense oligonucleotides, siRNA, miRNA, shRNA and ribozymes. Antisense or RNA
interference compounds specifically target ROCK nucleic acids. In one example, a ROCK
antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 (FIG. 12C) and/or human ROCK2 (FIG. 12D).
Several ROCK inhibitors are known in the art and have been described, for example, in the following references: U.S. Patent Nos. 4,997,834, 4,678,783 and 3,421,217, PCT publication No. W098/06433, W099/20620, W099/61403, W002/076976, W002/076977, W002/100833, W003/059913, W003/062227, W02004/009555, W02004/022541, W02004/108724, W02005/003101, W02005/039564, W02005/034866, W02005/037197, W02005/037198, W02005/035501, W02005/035503, W02005/035506, W02005/080394, W02005/103050, W02006/057270, W02006/058120, W02007/042321, W02007/006547, W02007/026664, W02008/049919, W02010/032875, W02011/107608, W02011/062765, W02011/062766, W02011/130740, W02012/135697, W02012/146724, W02013/030367, W02013/030216, W02013/030366, W02013/112722, W02014/113620, W02014/068035, W02014/118133, W02014/134388, W02014/134391, W02015/002915, W02015/002926, W02015/054317, W02016/010950, W02016/028971, W02016/057306, W02016/112236, W02016/144936, W02017/123860, W02017/205709, W02018/009625, W02018/009627, W02018/009622, W02018/102325, WO/2018/108156, and the like. Such compounds can be produced according to the method described in each of the disclosed references Examples of representative ROCK inhibitors include Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S 7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof, for example a dihydrochloride salt of Y-27632.
In an embodiment, the subject suffers from rhinosinusitis, for example chronic rhinosinusitis (CRS). In an embodiment, the rhinosinusitis is associated with a bacterial infection, e.g., infectious CRS. Bacterial strains associated with rhinosinusitis include Staphylococcus epidermidis, Staphylococcus aureus, Prop/on/bacterium, Streptococcus pneumoniae, G16612.00005 Haemophilus influenzae, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae and Moraxella catarrhalis. In an embodiment, the subject suffers from rhinosinusitis (e.g., CRS) with Staphylococcus aureus infection.
Thus, in another aspect, the present disclosure provides a method for treating rhinosinusitis (e.g., CRS) in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK signaling pathway inhibitor. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for treating rhinosinusitis (e.g., CRS) in a subject. The present disclosure also provides the use of a Rho/ROCK
signaling pathway inhibitor for the manufacture of a medicament for treating rhinosinusitis (e.g., CRS) in a subject.
The present disclosure also provides a Rho/ROCK signaling pathway inhibitor for treating rhinosinusitis (e.g., CRS) in a subject.
As used herein, the term "treat", "treating" or "treatment" is not intended to be absolute terms. Treatment can refer to any delay in onset, reduction in the frequency or severity of symptoms, amelioration of one or more symptoms, improvement in patient comfort and/or respiratory function, etc. The effect of treatment can be compared to an individual or pool of individuals not receiving a given treatment, or to the same patient prior to, or after cessation of, treatment.
In an embodiment, the patient had not undergone sinus surgery prior to said treatment.
In another embodiment, the patient had undergone sinus surgery (endoscopic sinus surgery, ESS) prior to said treatment.
In an embodiment, the patient is suffering from steroid-resistant CRS or refractory CRS.
The expression "patients suffering from refractory CRS" as used herein refers to patients with CRS refractory to medical and surgical therapy as defined by failure of technically adequate surgery followed by irrigations with a steroid (e.g., a corticosteroid such as budesonide) solution1'22 to eliminate the signs and symptoms of CRS. In an embodiment, the patient is non-responsive to a treatment with an anti-inflammatory agent (e.g., steroid), i.e. in whom cessation of anti-inflammatory agent (e.g., steroid) treatment results in no significant deterioration of the signs and/or symptoms of CRS. In another embodiment, the patient is responsive to a treatment with an anti-inflammatory agent (e.g., steroid), i.e. in whom cessation of anti-inflammatory agent (e.g., steroid) treatment results in deterioration of signs and/or symptoms of CRS (i.e., one or more of the symptoms and/or conditions described below). In an embodiment, the subject suffers from CRS with nasal polyps (CRSwNP).
In an embodiment, the treatment comprises improvement of at least one sinus conditions. In another embodiment, the treatment comprises improvement of at least one quality-of-life (QOL) parameters. In another embodiment, the treatment comprises improvement of sinus mucosal aspect. In an embodiment, the treatment comprises improvement of at least one sinus conditions, at least one QOL parameters, and sinus mucosal aspect. In another embodiment, the G16612.00005 treatment comprises improvement of at least one of the following CRS symptom parameters:
sino-nasal symptom score (SNSS), 22 item Sino-Nasal Outcome Test (SNOT-220, Washington University School of Medicine, St. Louis, Missouri) score and/or pen-operative sinus endoscopy (POSE) score.
The term "effective amount" refers to that amount of a therapeutic agent (e.g., ROCK
inhibitor) sufficient to promote sinonasal epithelial cell repair, e.g., to ameliorate one or more symptoms of rhinosinusitis (e.g., CRS). For example, for a given disease parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as "-fold" increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
For the prevention, treatment or reduction in the severity of a given disease or condition, the appropriate dosage of the compound/composition will depend on the type of disease or condition to be treated, the severity and course of the disease or condition, whether the compound/composition is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the compound/composition, and the discretion of the attending physician. The compound/composition is suitably administered to the patient at one time or over a series of treatments. Preferably, it is desirable to determine the dose-response curve in vitro, and then in useful animal models prior to testing in humans.
The present invention provides dosages for the compounds and compositions comprising same. For example, depending on the type and severity of the disease, about 1 pg/kg to to 1000 mg per kg (mg/kg) of body weight per day. Further, the effective dose may be 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg/ 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, and may increase by 25 mg/kg increments up to 1000 mg/kg, or may range between any two of the foregoing values. A typical daily dosage might range from about 1 pg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
In an embodiment, the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier or excipient.
As used herein, the term "pharmaceutically acceptable" is used synonymously with physiologically acceptable and pharmacologically acceptable with respect to, e.g., a pharmaceutical composition. A pharmaceutical composition will generally comprise agents for buffering and preservation in storage, and can include buffers and carriers for appropriate 016612.00005 delivery. Therapeutic formulations are prepared using standard methods known in the art by mixing the active ingredient(s) with one or more optional pharmaceutically acceptable carriers, excipients and/or stabilizers (see, e.g., Remington: The Science and Practice of Pharmacy, by Loyd V Allen, Jr, 2012, 22nd edition, Pharmaceutical Press; Handbook of Pharmaceutical .. Excipients, by Rowe et al., 2012, 791 edition, Pharmaceutical Press). The composition defined herein may be prepared in any suitable form which does not negatively affect the active agent(s) present in the composition. Selection of the excipients and the most appropriate methods for formulation in view of the particular purpose of the composition is within the scope of ordinary persons skilled in the art of pharmaceutical technology.
In some embodiments, the Rho/ROCK signaling pathway inhibitor or composition comprising same is for sinus administration/delivery. Sinus administration may be performed using an inhalation device, a nasal/sinus implant or stent, a spray, an aerosol, a syringe, nasal drops, nebulization, atomization, by flushing, or by irrigation. In an embodiment, the administration is performed by sinus rinse or irrigation, e.g., irrigation to the nasal and sinus passages. Sinus delivery/administration may be achieved/performed using commercially available kits or systems, e.g., NeilMed SINUS RINSETM system, hydraSense NetiRinse Nasal & Sinus Irrigation Kit, SinuPulseTM Elite Advanced Nasal Sinus Irrigation System, XIearTM Sinus Care Rinse system, Optinose , or Navage irrigator devices. In an embodiment, the Rho/ROCK
signaling pathway inhibitor or composition is coated on a nasal/sinus implant or stent, e.g. a drug-eluting nasal/sinus implant or stent (see, e.g., Parikh etal., Pharmaceutics. 2014 Jun; 6(2): 249-267).
In an embodiment, the compositions defined herein further comprise one or more excipients commonly used in nasal formulations (e.g., nasal sprays), such as water, preservatives (e.g., EDTA, benzalkonium chloride, benzethonium chloride, benzyl alcohol, chlorobutanol, nnethylparaben, phenylethyl alcohol, phenylmercuric acetate, propylene paraben, thimerosal), buffer salts or tonicity agents (e.g., sodium chloride, potassium chloride, glycerol, glycine), viscosity modifying agents (e.g., Me-OH-Pr cellulose, Na-CMC, microcrystalline cellulose), surfactants (glyceryl monoleate, lecithin, polysorbate 20 or 80) suspending agents/solvents (PEG), pH adjusting agents (acetic and citric acids, NaOH, HCI), mucoadhesive polymers (e.g., HPMC, chitosan), fillers/binders (e.g., cellulose-based polymers, maltodextrin, propylene glycol, colloidal silicon dioxide, guar gum) and flavors (e.g., menthol, saccharin sodium, sorbitol).
In an embodiment, the Rho/ROCK signaling pathway inhibitor or composition comprising same is used in combination another therapeutic agent. For example, the Rho/ROCK signaling pathway inhibitor or composition comprising same may be used with agents or therapies used in the treatment of CRS, such as topical intranasal steroids (e.g., prednisone, budenoside), oral antibiotics (e.g., fluoroquinolones, amoxicillin, amoxicillin¨clavulanate acid combinations), topical antibiotics, nasal saline irrigation, statins , probiotics, surgery (e.g., endoscopic sinus surgery), oral steroids or combination of oral antibiotics and steroids. The combination of agents may be G16612.00005 co-administered (e.g., consecutively, simultaneously, at different times). In an embodiment, the co-administration is coextensive, i.e. occurs during overlapping periods of time. In another embodiment, the Rho/ROCK signaling pathway inhibitor or composition comprising same and the other agent/therapy are administered consecutively. In an embodiment, the Rho/ROCK signaling 5 pathway inhibitor and the other active agent are formulated in the same composition. In another embodiment, the Rho/ROCK signaling pathway inhibitor and the other active agent are formulated in separate compositions. In another embodiment, the Rho/ROCK signaling pathway inhibitor and the other active agent are in different compositions, but these compositions are present together in the same kit or package. The kit or package can optionally include one or more containers, 10 saline solutions (e.g., to reconstitute lyophilized, spray-dried or freeze-dried compositions prior to administration), buffers, written instructions, reference to an internet site, or electronic instructions (e.g. on a support such as a CD-ROM, DVD, USB flash drive), and more particularly instructions for performing the methods and uses described herein, i.e. for treating CRS in a patient.
The subject/patient to be treated may be a child, an adult or an elderly. In an 15 embodiment, the subject/patient is an adult or an elderly.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention is illustrated in further details by the following non-limiting examples.
Example 1: Materials and Methods A total of 35 samples, composed of 19 cases of CRSwNP and 16 controls were included in this study. The demographic data for each group is presented in Table 1.
Table 1: Demographic data of patients whose samples were used at the present study.
Data are presented by frequency of events.
Data CRSwNP Control Age 51.0 9.5 50.3 18.1 Gender 10F/16M 8F/8M
Previous ESS 10/26 Asthma 6/26 0/16 Smoking 6/26 1/16 IgE 100 Ul/mL 5/26 ESS: endoscopic sinus surgery; AERD: aspirin-exacerbated respiratory disease;
IgE: immunoglobulin E
G16612.00005 Surgical sample collection, cell isolation and primary culture.
CRSwNP diagnosis was performed according to the 2004 AAO-HNS guidelines31, and patients underwent ESS following failure of medical treatment. Control patients underwent ESS
for cerebral spinal fluid leak or non-secreting pituitary adenomas. Exclusion criteria for both groups comprised immune deficiencies, neoplasia, ciliary dyskinesia, cystic fibrosis, and systemic immunosuppression. Tissues obtained during surgery at the level of anterior ethmoidal bulla (control) or the polyp itself (CRSwNP) were immediately collected for subsequent cell isolation and culture.
After recovery, pNECs were isolated following a standardized procedure32-35.
Briefly, collected samples were immediately rinsed and incubated overnight at 4 C in MEM (minimum essential medium) medium (Life Technologies Carlsbad, CA, USA) supplemented with 7.5%
NaHCO3(Sigma-Aldrich, Saint-Louis, MO, USA), 2 mM L-glutamine (Life Technologies), 10 mM
HEPES (Thermo Fisher Scientific, Waltham, MA, USA), 0.05 mg/mL gentamycin (Sandoz, Boucherville, QC, Canada), 50 U/mL penicillin-streptomycin, 0.25 pg/mL
Fungizone (Life Technologies), 0.1 % protease and 10 pg/mL DNase (Sigma-Aldrich).
After 18h, Fetal Bovine Serum was added to the solution to neutralize the protease-DNase activity, and pNECs were gently scraped off the remaining tissue.
Following removal of red blood cells by treatment with ACK lysis buffer (0.1 mM NH4CI, 10 pM KHCO3, 10 nM EDTA), the cell suspension was characterized by immunodetection of specific epithelial markers which indicated a mix of basal (CK13-positive), ciliated (p-tubulin-positive) and goblet (MUC5AC-positive) cells. This freshly isolated pNECs suspension was then seeded in T75 flasks coated with Purecol (Cedarlane Laboratory, Burlington, ON, Canada), and grown in CnT-17 to expend progenitor 0K13-positive basal cells, until confluency (CelInTec Advanced Cell Systems, Bern, Switzerland) medium, supplemented with 100U/mL penicillin and streptomycin.
pNECs were then detached by trypsin solution; 100 000 cells (second passage) were seeded into 24-well plastic plates (Corning, NY, USA), and cultured in CnT-17. At 80% confluency, the CnT-17 medium was replaced by a mix of 1:1 volume of BEGM (bronchial epithelial cell growth medium - Lonza CC4175, Basel, CH) and DMEM (Dulbecco's Modified Eagle's Medium - Thermo Fisher Scientific), supplemented with 1.5 pg/ml BSA, lx 10-7 M retinoic acid and 100 Wm: of penicillin-strept0mycin32-35.
S. aureus strains S. aureus (Rosenbach ATCC 25923 strain, Manassas, VA, USA) was cultured in Luria Bertani (LB, Difco, Montreal, QC, CA) agar, under agitation at 250 rpm at 37 C. Planktonic bacterial cultures at stationary phase after 24h of growth were centrifuged at 7,200 g for 10 min at room temperature. The supernatant was filtered with 0.22 vt.m cellulose acetate filters (Corning) G16612.00005 to remove bacteria, and filtrates, containing SA exoproducts, were aliquoted and stored at -80 C.
One aliquot of this filtrate was heated at 95 C for 15 minutes to inactivate protease activity (for comparison to non-heat inactivated aliquots). This aliquot was cooled after heating and stored for future assays.
Wound healing assay pNECs were injured mechanically (3 wounds / well, 3 wells / condition), using a well-established, highly reproducible technique2,34-37. After wounding, the cultures were washed to remove detached cells, and then randomly treated in either of the following conditions (performed in triplicate): 1) negative control: 0.5% (v/v) of LB, 2) exposure to SA
exoproducts, (at both concentrations of 0.25% and 0.5% (v/v) SA filtrate), and 3) exposure to SA
exoproducts (both concentrations of 0.25% and 0.5% (v/v) SA filtrate) and the ROCK inhibitor Y-dihydrochloride (5 p.M, Sigma-Aldrich ).
As a final assay, heat-inactivated-SA exoproducts were used, and the epithelial repair rates were reassessed, at the following conditions: 1) negative control: 0.5%
(v/v) of LB, 2) exposure to SA exoproducts (at concentration of 0.5% (v/v) SA filtrate) and 3) exposure to heat-inactivated SA exoproducts (concentration of 0.5% (v/v) SA filtrate).
A mark on wells allowed us to capture images of the wounds at exactly the same place at t=Oh and t=6h using an inverted microscope with a 4x objective (Nikon EclipseTM TE 2000).
Images were registered using AxioVision TM 4.8 software (Carl Zeiss, Jena, Germany) and then analyzed with Image J software (NIH, Bethesda, MD, USA) to measure areas at t=Oh and t=6h of wound healing and then to calculate the repair rates (expressed in 1.im2/h).
Analysis of Lamellipodial Dynamics by Kymograph Brightfield time-lapse series were made on pNECs from patients with CRSwNP and control subjects plated in 2-well silicone culture inserts (Ibidi #80209, Fitchburg, USA) using an inverted Axio ObserverZ1 microscope equipped with a CoolSNAPTM EZ CCD camera and a 10x/0.3 NA air objective lens, and then analyzed by AxioVision TM software.
Immediately prior to image acquisition, cells were treated with LB (control condition for SA) or LB + water (control condition for SA+Y-27632). Cells were then positioned into the incubation chamber (37 C, 5% CO2) and images were captured every minute for 2h to observe cell protrusions and retractions. Then, cells were treated with either SA
exoproducts (concentration of 0.5% (v/v)) or a mix of SA (concentration of 0.5% v/v) and Y-27632 (5 pM), with the recording pursued during the following 4h.
For each patient, on each time-lapse series, 4 to 6 cells exhibiting lamellipodia with consistent and dynamic protrusion/retraction cycles were randomly chosen for analysis. A one pixel-wide line crossing the cell membrane perpendicularly to the lamellipodia was drawn, and G16612.00005 this region was extracted from each image of the time-lapse series, as previously described by Choi et a/.38. Kymographs (time-space plots) were generated with the "Multiple Kymograph" plugin (J. Rietdorf, FMI Basel and A. Seitz, EMBL, Heidelberg, Germany) for ImageJ.
On kymographs, the x-axis represents time while the y-axis is the distance, where each protrusion/retraction cycle appears as a peak (FIG. 8). On each kymograph, segments following protrusions were manually retraced with the ImageJ segmented line tool. Data derived from these segmented lines were generated using "read velocity tsp macro" of ImageJ and used to calculate the length and velocity of each protrusion. At least a total of 40-110 individual protrusion events per condition and at least 14 different cells were analyzed in 3 independent time-lapse series.
lmmunofluorescence pNECs were grown to confluency on coverslips (precision cover glasses thickness No.
1.5H, Marienfeld, Lauda-Konigshofen, Germany) coated with PurecolTM. After injury, (3 mechanical wounds / coverslip), cell monolayers were washed and then treated with either: 1) LB
(concentration of 0.5% (v/v)): negative control, 2) SA exoproducts (concentration of 0.5% (v/v) SA
filtrate) and 3) SA exoproducts (concentration of 0.5% (v/v) SA filtrate) and Y-27632 (5p.M). After 4h of repair, cell monolayers were fixed with 4% paraformaldehyde in PBS for 5 min, permeabilized with 0.1% Triton TM X-100 in PBS for 10 min. After blocking (in 1% BSA in PBS for at least 1h at 4 C), fixed cells were incubated with the primary anti-p-tubulin antibody (1:1000 in PBS+BSA1%, Millipore, Etobicoke, Canada) for 1h at room temperature, and then with Alexa Fluor -488 conjugated goat anti-mouse antibody secondary antibody (1:2000 in PBS+BSA1%,1h, room temperature Thermo Fischer Scientific, Waltham, USA). F-actin was stained with Phalloidin-Alexa Fluor 594(1 unit, Thermo Fischer Scientific) (in PBS+BSA1%, for 1h at room temperature) and nuclei with DAPI (1:1000 in PBS+BSA1%, for 5 min). Coverslips were mounted with ProLong Gold Antifade Reagent (Molecular Probes, Eugene, USA) on SuperFrostTM glass slides (Thermo Fisher Scientific). Images were acquired with an inverted confocal microscope (TCS SP5, Leica Microsystems, Wetzlar, Germany) using an oil-immersion objective 63X/1.4. On immunofluorescence images, cells at the wound edge were classified according to the categories "with" or "without" lamellipodia as well as "ambiguous morphology" (see FIG.
10)39. Percentages of cells in each category were then calculated.
Statistical Analysis The data from all experiments are presented as mean SEM. ANOVA with Bonferroni post-hoc tests were used to compare the different conditions in the same group, and to compare the same condition between groups. Comparisons were considered statistically significant if p<0.05. In figures, statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***) G16612.00005 or non-significant (NS), GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA) was used to analyze all results.
Example 2: Effect of SA on control and CRSwNP samples During the last years, sinonasal epithelium has been intrinsically imbricated to CRSwNP
physiopathology. Indeed, the epithelial barrier defense is determinant to maintain mucosal homeostasis, either due to its physical (avoiding the entrance of pathogens) and functional implication (defense against pathogens through the release of inflammatory and antimicrobial substances)40-43. To this end, the epithelium is a key inducer of both innate and adaptive inf1ammati0e-43. Very recently, Schleimer43 proposed that mucosal injury and repair may be a key process at CRSwNP: a prolonged loss of barrier function of the epithelium may facilitate the entrance of pathogens / inhalants, and thus facilitate chronic inflammation.
It was thus evaluated whether the ability of nasal epithelia to repair differed between CRSwNP and control samples under baseline culture conditions. For this purpose, pNECs from controls and CRSwNP were cultured in parallel, in the same conditions, and then wounded, to compare their repair rates. The 2D cultures are predominantly composed of basal progenitor cells, playing a critical role in epithelial repair through their ability to migrate into the injured area and then proliferate". Repair rate analysis (FIGs. 1A, 1B) in each pNECs cultures from control subjects and CRSwNP patients (CRSwNP) revealed a variability among individual within each group. However, the mean wound repair rates were significantly slower (p<0.001) in pNECs monolayers from CRSwNP than controls, under baseline conditions (LB) (FIG. 1B).
It was then assessed whether exposure to SA exoproducts could alter the wound healing capacity of pNECs epithelia. A significant decrease in the repair of control pNECs monolayers was observed in the presence of 0.25% SA exoproducts (FIG. 2A). A stronger inhibitory effect (p<0.001) was observed after exposure to SA exoproducts at 0.5% (41% decrease compare to the repair rates in LB condition). A dose dependent inhibition of wound repair was observed in CRSwNP monolayers (34% and 69% decrease in the presence of SA 0.25% (p<0.01 vs. LB) and SA 0.5% (p<0.01 vs. LB), respectively (FIG. 2B).
To determine which component could be responsible for this deleterious response, heat-inactivated SA 0.5% exoproducts (SAnactive) were used, and their effect on the epithelial repair of pNECs monolayers from CRSwNP patients was reassessed (FIG. 9). It was observed that the epithelial repair was only weakly influenced by heat-inactivated SA 0.5%
exoproducts (SAnactive VS. LB: 14% decrease, non-significant), in contrast to active SA 0.5%
exoproducts within the same pNECs cultures (LB vs. SA: 88% decrease, p<0.001; and SA vs. SA,: 86%
increase, p<0.001).
Epithelial repair is dependent on several mechanisms, one of them being the coordinated and directional cell migration45. To optimize this lively process, the actin filaments organize themselves in a dynamic network, and create a sheet-like membrane protrusion, known as G16612.00005 Lamellipodia formation and orientation was thus further evaluated using video kymograph analysis. It was first confirmed that LB per se had no effect on cell movement.
Kymographs of pNECs cultures for both controls and CRSwNP before and after exposure to SA
exoproducts were subsequently evaluated.
5 Control cells depicted a mean protrusion length and velocity of 10.5 1.36 pm and 1.62 0.24 pm/min, respectively, in LB conditions. Subsequent exposure to SA
exoproducts (SA
0-2h) induced a 57% (p<0.01) and 60% (p<0.05) decrease in protrusion length and velocity, respectively, followed by a partial recovery of these parameters during the final two hours of the study observation (SA 2-4h) (FIG. 3A, 3B). In CRSwNP cells, both protrusion length (6.23 0.99 10 pm) and velocity (0.78 0.11 pm/min) were altered at baseline (LB
condition) and the exposure to SA exoproducts significantly worsened the levels of protrusion length and velocity. Moreover, in contrast with control pNECs, the effect of SA was persistent throughout the entire period following exposure to SA exoproducts (SA 0-2h and SA 2-4h).
Finally, the cellular cytoskeleton organization was evaluated by immunofluorescence 15 experiments. Microtubules and actin microfilaments were stained with a specific 13-tubulin antibody and with fluorescent phalloidin, respectively. Under LB condition, it was observed that the leading cells at the wound edge of injured pNECs monolayers from control subjects exhibited more pronounced lamellipodial extensions (see cells marked with an asterisk, FIG. 4A, merge) than the pNECs cultured from CRSwNP samples. However, control and CRSwNP pNECs 20 appeared to be correctly polarized and oriented towards the injured area (FIG. 4A). There was no substantial difference in F-actin or 13-tubulin distribution within the control and CRSwNP
pNECs. However, further analysis and lamellipodial cell quantification at the wound edge showed distinct patterns for control and CRSwNP pNECs (FIG. 4B). Indeed, the percentage of cells with lamellipodia was significantly lower in epithelia from CRSwNP patients than in those from control subjects (Control: 60% vs. CRSwNP: 41%), whereas the percentage of cells without lamellipodia was higher (Control: 8% vs. CRSwNP: 20%) (FIG. 4B).
Both control and CRSwNP pNECs were altered after exposure to SA exoproducts, exhibiting a more rounded shape, suggesting a loss in cell polarization, and a reorganization of the microtubule cytoskeleton, with an increase in microtubules localized circularly under the .. plasma membrane (FIG. 4A). Additionally, lamellipodial cell quantification showed that SA
exoproduct exposure induced significant decreases in the percentage of cells with lamellipodia at the wound edge (Control subjects: LB: 60% vs. SA: 25%; CRSwNP patients: LB:
41% vs. SA:
10%) (FIG. 4B). Conversely, the percentage of cells without lamellipodia is significantly increased after SA exoproduct exposure in epithelia from control subjects (LB: 8% vs.
SA: 34%) and CRSwNP patients (LB: 20% vs. SA: 45%) (FIG. 4B).
Example 3: Effect of ROCK inhibition on epithelial repair in pNECs G16612.00005 The effect of a potent Rho kinase (ROCK) inhibitor, Y-27632, on epithelial repair in pNECs exposed to SA exoproducts was assessed. It was first determined, in a pilot study, that 5 IV1 was the optimal dose for Y-27632 in pNEC. Indeed, treatment with 5 [INA of Y-27632, in LB
condition, led to an increase in epithelial repair rate of 23%, while increasing concentrations altered migration and induced pNECs apoptosis pNECs monolayers were then exposed to SA exoproducts either in the presence or absence of Y-27632 (5 M) (FIG. 5). The drug inhibited the deleterious effect of SA, increasing significantly the repair rates by almost 2-fold (1.86-fold) when co-cultured with SA 0.25%, and by 2.22-fold with SA 0.5%, compared to corresponding SA conditions in the absence of Y-27632.
It was also assessed whether the beneficial effect of Y-27632 on epithelial repair in the presence of SA exoproducts was related to an improvement in lamellipodial dynamics and migration. Whereas both protrusion length and velocity in CRSwNP pNECs were altered by the exposure to SA exoproducts (FIG. 3), this deleterious effect was no longer observed (FIG. 6) when CRSwNP pNECs were exposed simultaneously to SA 0.5% and Y-27632. Indeed, the length and the velocity of protrusions measured after treatments with SA+Y
were similar to those observed in the absence of SA (FIG. 6, LB vs. SA+Y). Finally, the cellular cytoskeleton organization after exposure to SA, in the absence and presence of Y-27632, was compared. It was first confirmed that, in the absence of Y-27632, SA exposure induced the cells to adopt a rounded shape, with lamellipodial extension substantially compromised at the leading edge of injury (FIG. 7A). Treatment with Y-27632 partially restored lamellipodial extensions: although the extension was not as prominent as under baseline conditions, most of the cells at the leading edge presented a more elongated shape and exhibited the lamellipodia pattern directed towards the injured area (FIG. 7A, see cells marked with an asterisk at the leading edge in LB and SA+Y
conditions). Interestingly, lamellipodial cell quantification showed that, after exposure to SA
exoproduct combined with the Y-27632 compound, injured epithelia from CRSwNP
patients exhibited significantly more cells with lamellipodia (SA: 13% vs. SA+Y: 65%) and significantly less cells without lamellipodia (SA: 43% vs. SA+Y: 8%) (FIG. 7B), confirming that ROCK inhibition improves lamellipodial dynamics and migration.
Although the present invention has been described hereinabove by way of specific embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The singular forms "a", "an" and "the" include corresponding plural references unless the context clearly dictates otherwise.
G16612.00005 REFERENCES
1. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al.
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol.
2016;6:S22-209. DOI: 10.1002/alr.21695.
2. DeConde AS, Soler ZM. Chronic rhinosinusitis: Epidemiology and burden of disease. Am J
Rhino! Allergy. 2016;30:134-9. DOI: 10.250/ajra.2016.30.4297.
3. Soler ZM, Wittenberg E, Schlosser RJ, MacE JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121:2672-8.
DOI:
10.1002/lary.21847.
4. Erskine S, Hopkins C, Kumar N, Wilson J, Clark A, Robertson A, et al. A
cross sectional analysis of a case-control study about quality of life in CRS in the UK; a comparison between CRS subtypes. Rhinology. 2016;54:311-5. DOI: 10.4193/Rhino15.361.
5. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope.
2017;127(3):550-5. DOI: 10.1002/lary.26391 6. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the english national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis.
Laryngoscope. 2009;119:2459-65. DOI: 10.1002/lary.20653 7. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al.
Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN-y and IL-4.
J Allergy Clin Immunol. 2012;130:1087-96. DOI: 10.1016/j.jaci.2012.05.052.
8. Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al.
Oncostatin M
promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015; 136:737-46.
DOI:
10.1016/j.jaci.2015.01.043.
9. Loxham M, Davies DE. Phenotypic and genetic aspects of epithelial barrier function in asthmatic patients. J Allergy Clin Immunol.
2017;139:1736-51. DOI:
10.1016/j.jaci.2017.04.005.
10. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014;134:509-20. DOI:
10.1016/j.jaci.2014.05.049.
11. Yu XM, Li CW, Chao SS, Li YY, Yan Y, Zhao XN, et al. Reduced growth and proliferation dynamics of nasal epithelial stem/progenitor cells in nasal polyps in vitro.
Sci Rep.
2014;4:4619. DOI: 10.1038/srep04619.
12. Yu XM, Li CW, Li YY, Liu J, Lin Z Bin, Li TY, et al. Down-regulation of EMP1 is associated with epithelial hyperplasia and metaplasia in nasal polyps. Histopathology.
2013;63:686-95.
G16612.00005 DOI: 10.1111/his.12211.
13. Bosse Y, Bacot F, Montpetit A, Rung J, Qu HQ, Engert JC, et al.
Identification of susceptibility genes for complex diseases using pooling-based genome-wide association scans.
Hum Genet. 2009;125:305-18. DOI 10.1007/s00439-009-0626-9.
14. Thanasumpun T, Batra PS. Endoscopically-derived bacterial cultures in chronic rhinosinusitis: A systematic review. Am J Otolaryngol - Head Neck Med Surg.
2015;36:686-91. DOI: 10.1016/j.amjoto.2015.04.010 15. Zhang Z, Adappa ND, Doghramji LJ, Chiu AG, Cohen NA, Palmer JN. Different clinical factors associated with Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015;5:724-33. DOI:
10.1002/alr.21532 16. Corriveau MN, Zhang N, Holtappels G, Van Roy N, Bachert C. Detection of Staphylococcus aureus in nasal tissue with peptide nucleic acid-fluorescence in situ hybridization. Am J
Rhinol Allergy. 2009;23:461-5. DOI: 10.2500/ajra.2009.23.3367.
17. Tan NCW, Foreman A, Jardeleza C, Douglas R, Vreugde S, Wormald PJ.
Intracellular Staphylococcus aureus: The Trojan horse of recalcitrant chronic rhinosinusitis? Int Forum Allergy Rhinol. 2013;3:261-6. DOI: 10.1002/alr.21154.
18. Kim RJT, Yin T, Chen CJJ, Mansell CJ, Wood A, Dunbar PR, et al. The interaction between bacteria and mucosal immunity in chronic rhinosinusitis: A prospective cross-sectional analysis. Am J Rhinol Allergy. 2013;27:183-90. DOI: 10.2500/ajra.2013.27.3974.
19. Tan NCW, Cooksley CM, Roscioli E, Drilling AJ, Douglas R, Wormald PJ, et al. Small-colony variants and phenotype switching of intracellular Staphylococcus aureus in chronic rhinosinusitis. Allergy. 2014;69:1364-71. D01:10.1111/a11.12457.
20. Kohanski MA, Lane AP. Sinonasal epithelial cell response to Staphylococcus aureus burden in chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2015;141:341-9.
DOI:
10.1001/jamaoto.2014.3550.
21. Gevaert E, Zhang N, Krysko 0, Lan F, Holtappels GE, De Ruyck N, et al.
Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol.
2017;139:1849-60. DOI: 10.1016/j.jaci.2017.01.019.
22. Teufelberger AR, Nordengrun M, Braun H, Maes T, De Grove K, Holtappels G, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by the Staphylococcus aureus protease SpID. J Allergy Clin lmmunol. 2017; Epub Ahead. DOI:
10.1016/j.jaci.2017.05.004.
23. Malik Z, Roscioli E, Murphy J, Ou J, Bassiouni A, Wormald PJ, et al.
Staphylococcus aureus impairs the airway epithelial barrier in vitro. Int Forum Allergy Rhinol.
2015;5:551-6. DOI:
10.1002/alr.21517.
24. Seop Kim C, Jeon S-Y, Min Y-G, Rhyoo C, Kim J-W, Bock Yun J, et al.
Effects of 13-Toxin of Staphylococcus aureus on Ciliary Activity of Nasal Epithelial Cells.
Laryngoscope.
G16612.00005 2000;110:2085-8.
25. Eiffler I, Behnke J, Ziesemer S, Muller C, Hildebrandt J-P. Staphylococcus aureus a-toxin-mediated cation entry depolarizes membrane potential and activates p38 MAP
kinase in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016;311:L676-85.
DOI:
10.1152/ajplung.00090.2016.
26. Hermann I, Rath S, Ziesemer S, Volksdorf T, Dress RJ, Gutjahr M, et al.
Staphylococcus aureus hemolysin A disrupts cell-matrix adhesions in human airway epithelial cells. Am J
Respir Cell Mol Biol. 2015;52:14-24. DOI: 10.1165/rcmb.2014-00820C.
27. Yin J, Yu F-SX. Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol. 2008;295:378-87. D01:10.1152/ajpce11.90624.2007.
28. Elamin E, Masclee A, Dekker J, Jonkers D. Ethanol disrupts intestinal epithelial tight junction integrity through intracellular calcium-mediated Rho/ROCK activation. Am J
Physiol Gastrointest Liver Physiol. 2014;306:G677-85. 001: 10.1152/ajpgi.00236.2013.
29. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J
Physiol Lung Cell Mol Physiol. 2010;298: L715-31. DOI: 10.1152/ajplung.00361.2009.
30. Sun CC, Chiu HT, Lin YE, Lee KY, Pang JHS. Y-27632, a ROCK inhibitor, promoted limbal epithelial cell proliferation and corneal wound healing. PLoS One. 2015;10:1-18.
D01:10.1371/journal.pone.0144571.
31. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BE, Nicklas RA, et al.
Rhinosinusitis:
Establishing definitions for clinical research and patient care. J Allergy Clin Immunol.
2004;114:5155-212. D01:10.1016/j.jaci.2004.09.029.
32. Ruffin M, Bilodeau C, Maille E, LaFayette SL, McKay GA, Trinh NTN, et al.
Quorum-sensing inhibition abrogates the deleterious impact of Pseudomonas aeruginosa on airway epithelial repair. FASEB J. 2016;30:3011-25. DOI: 10.1096/fj.201500166R.
33. Trinh NT, Bilodeau C, Male E, Ruffin M, Quintal M, Desrosiers M, et al.
Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur Respir J. 2015;45:1590-602. DOI:
10.1183/09031936.00076214 34. Trinh N, Bardou 0, Prive A, Maine E, Adam D, Lingee S, Ferraro P, Desrosiers M, Coraux C
BE. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR
rescue. Eur Respir J. 2012;40:1390-400. DOI: 10.1183/09031936.00221711.
35. Bilodeau C, Bardou 0, Male E, Berthiaume Y, Brochiero E. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J
Cyst Fibros.
2016;15:43-51. DOI: 10.1016/j.jcf.2015.04.002.
36. Maine E, Trinh NTN, Prive A, Bilodeau C, Bissonnette E, Grandvaux N, et al. Regulation of normal and cystic fibrosis airway epithelial repair processes by TNF-a after injury. Am J
Physiol Lung Cell Mol Physiol. 2011;301:L945-55. DOI:
10.1152/ajplung.00149.2011.
G16612.00005 37. Trinh NTN, Prive A, MaiIle E, Noel J, Brochiero E. EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. Am J Physiol Lung Cell Mol Physiol.
2008;295:L866-80. DOI: 10.1152/ajplung.90224.2008.
38. Choi S, Camp SM, Dan A, Garcia JG, Dudek SM, Leckband DE. A genetic variant of cortactin linked to acute lung injury impair lamellipodia dynamics and endothelial wound healing. Am J Physiol Lung Cell Mol Physiol. 2015;3091983-94. DOI:
10.1152/ajplung.00062.2015.
39. Steffen A, Rottner K, Ehinger J, Innocenti M, Scita G, Wehland J, et al.
Sra-1 and Nap1 link Rac to actin assembly driving lamellipodia formation. EMBO J. 2004;23:749-59.
40. Zhang N, van Crombruggen K, Gevaert E, Bachert C. Barrier function of the nasal mucosa in health and type-2 biased airway diseases. Allergy. 2016;71:295-307. DOI:
10.1111/a11.12809.
41. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF.
Endotype-driven treatment in chronic upper airways diseases. Clin Trans Allergy. 2017;7-22.
DOI:
10.1186/s13601-017-0157-8.
42. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J
Allergy Olin Immunol. 2015;136:1142-53. DOI: 10.1016/j.jaci.2015.10.009.
43. Schleimer RP. lmmunopathogenesis of chronic rhinosinusitis and nasal polyps. Annu Rev Pathol Mech Dis. 2017;12:331-57. DOI: 10.1146/annurev-pathol-052016-100401.
44. Duan C, Li OW, Zhao L, Subramaniam S, Yu XM, Li YY, et al. Differential expression patterns of egf, egfr, and erbb4 in nasal polyp epithelium. PLoS One. 2016;11:1-14.
DOI:
10.1371/journal.pone.0156949.
45. Desai LP. RhoA and Rac1 are both required for efficient wound closure of airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1134-44. DOI:
10.1152/ajplung.00022.2004.
46. de Bentzmann S, Polette M, Zahm J, Hinnrasky J, Kileztky C, Bajolet 0, et al. Pseudomonas Aeruginosa Virulence Factors Delay Airway Epithelial Wound Repair by Altering the Actin Cytoskeleton and Inducing Overactivation of Epithelial Matrix Metalloproteinase-2. Lab Invest. 2000;80:209-19.
47. Menko AS, Bleaken BM, Walker JL. Regional-specific alterations in cell-cell junctions, cytoskeletal networks and myosin-mediated mechanical cues coordinate collectivity of movement of epithelial cells in response to injury. Exp Cell Res. 2014;322:133-48. DOI:
10.1016/j.yexcr.2013.12.021.
48. Horani A, Nath A, Wasserman MG, Huang T, Brody SL. Rho-associated protein kinase inhibition enhances airway epithelial basal-cell proliferation and lentivirus transduction. Am J
Respir Cell Mol Biol. 2013;49:341-7. DOI: 10.1165/rcmb.2013-0046TE.
49. Moore M, Marroquin BA, Gugliotta W, Tse R, White SR. Rho Kinase Inhibition Initiates Apoptosis in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol.
2004;30:379-87. DOI:
G16612.00005 10.1165/rcmb.2003-00190C.
50. Zuo W, Zhang T, Wu DZ, Guan SP, Liew A-A, Yamamoto Y, et al.
p63+Krt5+ distal airway stem cells are essential for lung regeneration. Nature. 2014;517:616-20. DOI:
10.1038/nature13903.
51. Arason AJ, Jonsdottir HR, Halldorsson S, Benediktsdottir BE, Bergthorsson JT, Ingthorsson S, et al. DeltaNp63 has a role in maintaining epithelial integrity in airway epithelium. PLoS
One. 2014;9:e88683. 001:10.1371/journal.pone.0088683.
52. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J
Physiol Lung Cell Mol Physiol. 2010;298:L715-31. DOI: 10.1152/ajplung.00361.2009.
53. Marano RJ, Wallace HJ, Wijeratne D, Fear MW, Wong HS, O'Handley R.
Secreted biofilm factors adversely affect cellular wound healing responses in vitro. Sci Rep.
2015;5:13296.
D01:10.1038/srep13296 54. Brothers KM, Stella NA, Hunt KM, Romanowski EG, Liu X, Klarlund JK, et al.
Putting on the brakes: Bacterial impediment of wound healing. Sci Rep. 2015;5:14003 I DOI:
10.1038/srep14003.
55. Wise SK, Den Beste KA, Hoddeson EK, Parkos CA, Nusrat A. Sinonasal epithelial wound resealing in an in vitro model: Inhibition of wound closure with IL-4 exposure. Int Forum Allergy Rhinol. 2013;3:439-49. DOI: 10.1002/alr.21158.
Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.
BRIEF DESCRIPTION OF DRAWINGS
In the appended drawings:
FIGs. 1A and 1B show that nasal airway epithelial repair rate is poorest in CRSwNP
than in control epithelia under baseline conditions. Cell monolayers obtained from pNECs from control subjects or CRSwNP patients were mechanically injured and epithelial repair rates were measured over a 6h-period. FIG. 1A: Representative pictures of injured epithelia from a control subject (left) and a CRSwNP patient (right) were obtained from inverted microscope (4x). Pictures were taken immediately after the injury has been made (Oh, above) and after a 6h- period of repair (6h, below). Wounds have been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. FIG. 1B: Quantitative analysis of epithelial repair rate, from 15 patients in each group. Samples were derived at the same time and pNECs cultures were processed in parallel in order to compare control and CRSwNP repair rates. Differences between control and CRSwNP repair rates were assessed by one-way ANOVA
followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*).;
FIGs. 2A and 2B show that exposure to S. aureus exoproducts decreases nasal epithelial repair rates. pNECs monolayers obtained from control subjects (FIG.
2A) and CRSwNP
patients (FIG. 2B) were mechanically injured and treated with LB (left), SA
0.25% (middle) and SA 0.5% (right), and epithelial repair rates were measured over a 6h-period.
Upper panels:
Representative pictures of injured epithelia from a control subject (FIG. 2A) and a CRSwNP
patient (FIG. 2B) were obtained with an inverted microscope (4x). Pictures were taken immediately after injury (Oh, above) and after a 6h-period of repair (6h, below). Wounds have G16612.00005 been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. Quantitative analysis of epithelial repair rates, from 11 control subjects (FIG.
2A) and 12 CRSwNP patients (FIG. 2B), in control condition (LB) and after exposure to SA
exoproducts at 0.25% (v/v) and 0.5% (v/v). The values obtained in each condition were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).*;
FIGs. 3A and 3B show lamellipodial dynamics of control and CRSwNP nasal epithelial cells are affected by exposure to S. aureus exoproducts. pNECs from control subjects (FIG. 3A) or CRSwNP patients (FIG. 3B) were treated with LB at the beginning of the experiment and imaged every minute for 2 hours. Then, S. aureus exoproducts (SA) were added and recording were pursued for the next 4h (SA(0-2h) and SA(2-4h)). Upper panels:
representative kymographs taken from time-lapse series of pNECs from a control subject (FIG. 3A) and a patient with CRSwNP (FIG. 3B). Kymographs depict variations in lamellipodial activity along a one-pixel-wide line drawn perpendicularly to the cell membrane in sequential phase-contrast images. Ascending contours show lamellipodial protrusion, whereas descending contours show lamellipodial retraction. Lower panels: Quantitative analysis of lamellipodial dynamics in pNECs from control subjects (FIG. 3A) and CRSwNP patients (FIG. 3B). Length and velocity of protrusions were calculated from the slopes traced on the leading edge of cells on 14-15 kymographs (each kymograph was taken from one cell) from 3 controls (FIG. 3A) and 3 CRSwNP
patients (FIG. 3B).
Means were calculated for 3 distinct periods, t=Oh to t=2h (LB, control condition), t=2h to t=4h (SA
(0-2h)) and t=4h to t=6h (SA (2-4h)). Differences between groups (LB, SA (0-2h) and SA (2-4h)) were assessed by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).
FIGs. 4A and 4B show that exposure to S. aureus exoproducts affects cytoskeleton organization of nasal epithelia from control subjects and CRSwNP patients.
FIG. 4A:
Representative confocal microscopy images of nasal epithelia from control subjects and CRSwNP patients mechanically injured and treated with either LB (control condition) or S. aureus exoproducts (SA, 0.5%) for 4h. Cells were stained for microtubules (with anti-13-tubulin antibody, upper panels) and actin stress fibers (phalloidin staining, middle panels), and nuclei were labeled with DAPI. Cells were visualized using a Leica TCS SP5 confocal microscope (magnification x63).
Merged images are shown on lower panels. White asterisks indicate cell protrusions at the leading edge of the wounds. Insets are shown to emphasize the cell shapes. Scale bars represent 25 pm.
If necessary, images were rotated to place the wounds at the top of each photograph. FIG. 4B:
Results of the lamellipodial cell quantification. The percentages of cells with lamellipodia (dark grey), with ambiguous morphology (light grey) or without lamellipodia (white) at the wound edge were counted on immunofluorescences images of nasal epithelia from control subjects (Control) and CRSwNP patients (CRS) after mechanical injury and treatment with either LB
or SA
G16612.00005 exoproducts (SA 0.5%). Left panel shows the repartition (in c/o) of cells according the 3 categories.
Values are means SEM from n=4 independent experiments (at least 80 cells per condition were classified). Insert (right) shows the results of the statistical analysis.
Differences between groups were assessed by one-way ANOVA followed by Bonferroni post-hoc tests.
Statistical differences are indicated as follows: p<0.05 (*) and p<0.001 (***).
FIGs. 5A and 5B show that ROCK inhibitor Y-27632 prevented the deleterious effect of S. aureus on epithelial repair rates of CRSwNP nasal epithelial cells. pNECs monolayers from CRSwNP patients were injured, treated with LB + vehicle (water), SA (0.25%) +
vehicle (water) and SA (0.25%) + Y-27632, SA (0.5%) + vehicle (water) or SA (0.5%) + Y-27632, and then .. epithelial repair rates were calculated over a 6h period. FIG. 5A:
Representative pictures of injured epithelia from a CRSwNP patient were obtained in the different conditions and taken at Oh (above) and 6h (below) after injury with an inverted microscope (4x).
Wounds have been brightened on the pictures and dotted lines have been drawn along the wound edges for better visualization. FIG. 5B: Quantitative analysis of epithelial repair rates from 15 CRSwNP patients.
The values obtained from each condition within the same group were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***).
FIGs. 6A and 6B show that ROCK inhibition attenuates the negative impact of S.
aureus exoproducts on lamellipodial dynamics of nasal epithelial cells from CRSwNP.
pNECs monolayers from CRSwNP patients were treated with LB + vehicle (water) at the beginning of the experiment and imaged every minute for 2h. Then, a combination of 0.5% of SA
exoproducts and 5pM of the ROCK inhibitor Y-27632 (SA + Y) was added, and recording were pursued for the next 4h. FIG. 6A: Representative kymograph taken from phase-contrast time-lapse series of pNECs from a patient with CRSwNP (right). FIG. 6B: Quantitative analysis of lamellipodial dynamics.
Length (upper panels) and velocity (lower panels) of protrusions (left panels) and retractions (right panels) were calculated from the slopes traced on the leading edge of cells on 11 kymographs (each kymograph was taken from one cell) from 3 independent experiments (i.e.
3 CRSwNP
patients) (N=3 patients, n=11 cells). Means were calculated for 3 distinct periods, t=Oh to t=2h (LB, control condition), t=2h to t=4h (SA +Y (0-2h)) and t=4h to t=6h (SA + Y
(2-4h)). Differences between groups were assessed by repeated measures ANOVA followed by Bonferroni post-hoc tests. All comparisons were established as non-significant following statistical analysis (p>0.05).
FIGs. 7A and 7B show that ROCK inhibition protects cytoskeleton disorganization of nasal epithelial cells from CRSwNP due to S. aureus exoproduct exposure. FIG.
7A:
Representative confocal microscopy images of nasal epithelia from CRSwNP
patients mechanically injured and treated with either LB + vehicle (water, control condition), SA
exoproducts (SA 0.5%) + vehicle (water) or SA exoproducts and Y-27632 (SA 0.5%
+ Y-27632 5pM) for 4h. Cells were stained for microtubules (with an anti-8-tubu)in antibody, upper panels) G16612.00005 and actin stress fibers (phalloidin staining, middle panels), and nuclei were labeled with DAPI.
Cells were visualized using a Leica TCS SP5 confocal microscope (magnification x63). Merged images are shown on lower panels. White asterisks indicate protrusions at the leading edge of the wounds. Insets are shown to emphasize the cell shapes. Scale bars represent 25 pm. If necessary, images were rotated to place the wounds at the top of each photograph. FIG. 7B:
Results of lamellipodial cell quantification. The percentages of cells with lamellipodia (dark grey), with ambiguous morphology (light grey) or without lamellipodia (white) at the wound edge were counted on immunofluorescences images of nasal epithelia from control subjects (Control) and CRSwNP patients (CRS) after mechanical injury and treatment with either LB +
vehicle (LB), SA
exoproducts (SA 0.5%) + vehicle (SA) or SA exoproducts (SA 0.5%) + Y-27632 (Y-27632 5 pM) (SA+Y). Left panel shows the repartition (in %) of cells according the 3 categories. Values are means SEM from n=4 independent experiments (at least 110 cells per condition were classified).
Insert (right) shows the results of the statistical analysis. Differences between groups were assessed by one-way ANOVA followed by Bonferroni post-hoc tests. Statistical differences are indicated as follows: p<0.05 (*) and p<0.001 (***).
FIG. 8 shows a kymograph taken from a phase-contrast time-lapse series showing local protrusion¨retraction cycles. Dotted arrows indicate protrusion and retraction phases. Protrusion and retraction length and velocity were calculated using Multiple Kymograph and tsp050706 plugin for ImageJ by tracing a segmented line along the edge of lamellipodia on kymographs.
FIGs. 9A and 9B show that heat-inactivation of SA exoproducts prevents the negative impact of SA exoproducts on the repair rates of CRSwNP nasal epithelia. pNECs monolayers obtained from pNECs from CRSwNP patients were mechanically injured and treated with LB (left), SA exoproducts 0.5% (SA - middle) or heat-inactivated SA exoproducts 0.5%
(SArnactive - right) and epithelial repair rates were measured over a 6h-period. Heat inactivation was performed by heating SA exoproducts at 95 C for 15 minutes. FIG. 9A: Representative pictures were taken immediately after injury (Oh, upper panels) and after 6h of repair (6h, lower panels) with an inverted microscope (4x). Wounds have been brightened on the pictures and dotted lines have been drawn at the wound edges for a better visualization. FIG. 9B:
Quantitative analysis of epithelial repair rates, from 3 patients. The values obtained from each situation within the same group were compared by repeated measures ANOVA followed by Bonferroni post-hoc tests.
Statistical differences are indicated as p<0.001 (***) or non-significant (NS).
FIG. 10 depicts the lamellipodia quantification method used in the studies described herein. Example of cells classified according to the categories with or without lamellipodia as well as with ambiguous morphology. Percentages of cells in each category were then calculated.
FIGs. 11A-11C show the structure of representative ROCK inhibitors.
FIGs. 12A and 12B depict the amino acid sequences of human ROCK1 (UniProtKB -Q13464, SEQ ID NO:2) and ROCK2 (UniProtKB -075116, SEQ ID NO:4), respectively.
G16612.00005 FIGs. 12C and 12D depict the nucleotide sequences of the gene encoding human ROCK1 (FIG. 12C, SEQ ID NO:1) and human ROCK2 (FIG. 12D, SEQ ID NO:3), respectively.
DISCLOSURE OF INVENTION
The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All subsets of values within the ranges are also incorporated into the specification as if they were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Herein, the term "about" has its ordinary meaning. The term "about" is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10%
or 5% of the recited values (or range of values).
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In the studies described herein, the present inventors have shown that there is an intrinsic defect in epithelial repair in CRSwNP patients, and that SA
exoproduct exposure alters epithelial repair of normal cells and accentuate the abnormal repair in CRSwNP
cells.
Furthermore, the studies described herein demonstrate that the effect of SA on cell protrusion is more sustained over time in pNECs cultures from CRSwNP patients. The present inventors have also provided evidence that targeting the Rho/Rho kinase signaling pathway constitutes a new strategy to counteract the negative effect of SA, as the deleterious effect of SA on repair rate and lamellipodia of CRSwNP pNECs cultures was prevented by Rho-associated protein kinase G16612.00005 (ROCK) inhibition using the representative ROCK inhibitor Y-27632. These results provide compelling evidence that Rho/ROCK signaling pathway inhibition may be useful for promoting sinonasal epithelial cell repair, and consequently for the treatment of diseases/conditions associated with impairment of nasal and paranasal sinus mucosa integrity and/or sinonasal 5 epithelial repair and regeneration, such as rhinosinusitis.
Accordingly, in a first aspect, the present disclosure provides a method for promoting sinonasal epithelial cell repair in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK signaling pathway inhibitor. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial 10 .. cell repair in a subject. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for the manufacture of a medicament for promoting sinonasal epithelial cell repair in a subject. The present disclosure also provides a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
In an embodiment, the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor. The term "ROCK inhibitor" as used herein refers to a peptide, a protein, a nucleic acid (antisense oligonucleotides, RNA interference agents such as siRNAs, shRNAs, miRNAs, ribozymes), a small molecule, an antibody or other agent that prevents or reduces expression of ROCK or inhibits ROCK activity, such as its kinase activity.
ROCK is a serine/threonine kinase belonging to the AGC family of protein kinases, which .. are structurally related to myotonic dystrophy kinase (DMPK) and myotonic dystrophy kinase-related CDC42-binding kinase (MRCK). ROCK is composed of an N-terminal catalytic domain, a central coiled-coil domain, and a C-terminal Pleckstrin homology (PH) domain interrupted by a Cysteine-rich region. ROCK requires both N- and C-terminal extension segments in addition to the core catalytic domain for its activity, which is conserved among the DMPK
subgroup. Rho activates ROCK by binding to the C-terminal portion of the coiled-coil. The amino acid sequences of human ROCK1 (UniProtKB - Q13464, SEQ ID NO:2) and ROCK2 (UniProtKB -075116, SEQ
ID NO:4) are disclosed in FIG. 12A and FIG. 12B, respectively, and the nucleotides sequences of the cDNAs encoding human ROCK1 and ROCK2 are disclosed in FIG. 12C (SEQ ID
NO:1) and FIG. 12D (SEQ ID NO:3), respectively.
In an embodiment, the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 (FIG. 12A) and/or ROCK2 (FIG. 12B) and blocks its activity, for example by blocking its binding to one of its ligand or substrate. The term "antibody or antigen-binding fragment thereof" as used herein refers to any type of antibody/antibody fragment including monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies, humanized antibodies, CDR-grafted antibodies, chimeric antibodies and antibody fragments so long as they exhibit the desired antigenic specificity/binding activity. Antibody fragments comprise a portion of a full-length antibody, generally an antigen G16612.00005 binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules (e.g., single-chain FV, scFV), single domain antibodies (e.g., from camelids), shark NAR single domain antibodies, and multispecific antibodies formed from antibody fragments. Antibody fragments can also refer to binding moieties comprising CDRs or antigen binding domains including, but not limited to, VH
regions (VH, anticalins, PepBodies, antibody-T-cell epitope fusions (Troybodies) or Peptibodies.
In other embodiments, the ROCK inhibitor is an antisense or RNA interference compound. Antisense or RNA interference compounds include, but are not limited to, antisense oligonucleotides, siRNA, miRNA, shRNA and ribozymes. Antisense or RNA
interference compounds specifically target ROCK nucleic acids. In one example, a ROCK
antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 (FIG. 12C) and/or human ROCK2 (FIG. 12D).
Several ROCK inhibitors are known in the art and have been described, for example, in the following references: U.S. Patent Nos. 4,997,834, 4,678,783 and 3,421,217, PCT publication No. W098/06433, W099/20620, W099/61403, W002/076976, W002/076977, W002/100833, W003/059913, W003/062227, W02004/009555, W02004/022541, W02004/108724, W02005/003101, W02005/039564, W02005/034866, W02005/037197, W02005/037198, W02005/035501, W02005/035503, W02005/035506, W02005/080394, W02005/103050, W02006/057270, W02006/058120, W02007/042321, W02007/006547, W02007/026664, W02008/049919, W02010/032875, W02011/107608, W02011/062765, W02011/062766, W02011/130740, W02012/135697, W02012/146724, W02013/030367, W02013/030216, W02013/030366, W02013/112722, W02014/113620, W02014/068035, W02014/118133, W02014/134388, W02014/134391, W02015/002915, W02015/002926, W02015/054317, W02016/010950, W02016/028971, W02016/057306, W02016/112236, W02016/144936, W02017/123860, W02017/205709, W02018/009625, W02018/009627, W02018/009622, W02018/102325, WO/2018/108156, and the like. Such compounds can be produced according to the method described in each of the disclosed references Examples of representative ROCK inhibitors include Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S 7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof, for example a dihydrochloride salt of Y-27632.
In an embodiment, the subject suffers from rhinosinusitis, for example chronic rhinosinusitis (CRS). In an embodiment, the rhinosinusitis is associated with a bacterial infection, e.g., infectious CRS. Bacterial strains associated with rhinosinusitis include Staphylococcus epidermidis, Staphylococcus aureus, Prop/on/bacterium, Streptococcus pneumoniae, G16612.00005 Haemophilus influenzae, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae and Moraxella catarrhalis. In an embodiment, the subject suffers from rhinosinusitis (e.g., CRS) with Staphylococcus aureus infection.
Thus, in another aspect, the present disclosure provides a method for treating rhinosinusitis (e.g., CRS) in a subject in need thereof comprising administering to said subject an effective amount of a Rho/ROCK signaling pathway inhibitor. The present disclosure also provides the use of a Rho/ROCK signaling pathway inhibitor for treating rhinosinusitis (e.g., CRS) in a subject. The present disclosure also provides the use of a Rho/ROCK
signaling pathway inhibitor for the manufacture of a medicament for treating rhinosinusitis (e.g., CRS) in a subject.
The present disclosure also provides a Rho/ROCK signaling pathway inhibitor for treating rhinosinusitis (e.g., CRS) in a subject.
As used herein, the term "treat", "treating" or "treatment" is not intended to be absolute terms. Treatment can refer to any delay in onset, reduction in the frequency or severity of symptoms, amelioration of one or more symptoms, improvement in patient comfort and/or respiratory function, etc. The effect of treatment can be compared to an individual or pool of individuals not receiving a given treatment, or to the same patient prior to, or after cessation of, treatment.
In an embodiment, the patient had not undergone sinus surgery prior to said treatment.
In another embodiment, the patient had undergone sinus surgery (endoscopic sinus surgery, ESS) prior to said treatment.
In an embodiment, the patient is suffering from steroid-resistant CRS or refractory CRS.
The expression "patients suffering from refractory CRS" as used herein refers to patients with CRS refractory to medical and surgical therapy as defined by failure of technically adequate surgery followed by irrigations with a steroid (e.g., a corticosteroid such as budesonide) solution1'22 to eliminate the signs and symptoms of CRS. In an embodiment, the patient is non-responsive to a treatment with an anti-inflammatory agent (e.g., steroid), i.e. in whom cessation of anti-inflammatory agent (e.g., steroid) treatment results in no significant deterioration of the signs and/or symptoms of CRS. In another embodiment, the patient is responsive to a treatment with an anti-inflammatory agent (e.g., steroid), i.e. in whom cessation of anti-inflammatory agent (e.g., steroid) treatment results in deterioration of signs and/or symptoms of CRS (i.e., one or more of the symptoms and/or conditions described below). In an embodiment, the subject suffers from CRS with nasal polyps (CRSwNP).
In an embodiment, the treatment comprises improvement of at least one sinus conditions. In another embodiment, the treatment comprises improvement of at least one quality-of-life (QOL) parameters. In another embodiment, the treatment comprises improvement of sinus mucosal aspect. In an embodiment, the treatment comprises improvement of at least one sinus conditions, at least one QOL parameters, and sinus mucosal aspect. In another embodiment, the G16612.00005 treatment comprises improvement of at least one of the following CRS symptom parameters:
sino-nasal symptom score (SNSS), 22 item Sino-Nasal Outcome Test (SNOT-220, Washington University School of Medicine, St. Louis, Missouri) score and/or pen-operative sinus endoscopy (POSE) score.
The term "effective amount" refers to that amount of a therapeutic agent (e.g., ROCK
inhibitor) sufficient to promote sinonasal epithelial cell repair, e.g., to ameliorate one or more symptoms of rhinosinusitis (e.g., CRS). For example, for a given disease parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as "-fold" increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
For the prevention, treatment or reduction in the severity of a given disease or condition, the appropriate dosage of the compound/composition will depend on the type of disease or condition to be treated, the severity and course of the disease or condition, whether the compound/composition is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the compound/composition, and the discretion of the attending physician. The compound/composition is suitably administered to the patient at one time or over a series of treatments. Preferably, it is desirable to determine the dose-response curve in vitro, and then in useful animal models prior to testing in humans.
The present invention provides dosages for the compounds and compositions comprising same. For example, depending on the type and severity of the disease, about 1 pg/kg to to 1000 mg per kg (mg/kg) of body weight per day. Further, the effective dose may be 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg/ 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, and may increase by 25 mg/kg increments up to 1000 mg/kg, or may range between any two of the foregoing values. A typical daily dosage might range from about 1 pg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
In an embodiment, the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier or excipient.
As used herein, the term "pharmaceutically acceptable" is used synonymously with physiologically acceptable and pharmacologically acceptable with respect to, e.g., a pharmaceutical composition. A pharmaceutical composition will generally comprise agents for buffering and preservation in storage, and can include buffers and carriers for appropriate 016612.00005 delivery. Therapeutic formulations are prepared using standard methods known in the art by mixing the active ingredient(s) with one or more optional pharmaceutically acceptable carriers, excipients and/or stabilizers (see, e.g., Remington: The Science and Practice of Pharmacy, by Loyd V Allen, Jr, 2012, 22nd edition, Pharmaceutical Press; Handbook of Pharmaceutical .. Excipients, by Rowe et al., 2012, 791 edition, Pharmaceutical Press). The composition defined herein may be prepared in any suitable form which does not negatively affect the active agent(s) present in the composition. Selection of the excipients and the most appropriate methods for formulation in view of the particular purpose of the composition is within the scope of ordinary persons skilled in the art of pharmaceutical technology.
In some embodiments, the Rho/ROCK signaling pathway inhibitor or composition comprising same is for sinus administration/delivery. Sinus administration may be performed using an inhalation device, a nasal/sinus implant or stent, a spray, an aerosol, a syringe, nasal drops, nebulization, atomization, by flushing, or by irrigation. In an embodiment, the administration is performed by sinus rinse or irrigation, e.g., irrigation to the nasal and sinus passages. Sinus delivery/administration may be achieved/performed using commercially available kits or systems, e.g., NeilMed SINUS RINSETM system, hydraSense NetiRinse Nasal & Sinus Irrigation Kit, SinuPulseTM Elite Advanced Nasal Sinus Irrigation System, XIearTM Sinus Care Rinse system, Optinose , or Navage irrigator devices. In an embodiment, the Rho/ROCK
signaling pathway inhibitor or composition is coated on a nasal/sinus implant or stent, e.g. a drug-eluting nasal/sinus implant or stent (see, e.g., Parikh etal., Pharmaceutics. 2014 Jun; 6(2): 249-267).
In an embodiment, the compositions defined herein further comprise one or more excipients commonly used in nasal formulations (e.g., nasal sprays), such as water, preservatives (e.g., EDTA, benzalkonium chloride, benzethonium chloride, benzyl alcohol, chlorobutanol, nnethylparaben, phenylethyl alcohol, phenylmercuric acetate, propylene paraben, thimerosal), buffer salts or tonicity agents (e.g., sodium chloride, potassium chloride, glycerol, glycine), viscosity modifying agents (e.g., Me-OH-Pr cellulose, Na-CMC, microcrystalline cellulose), surfactants (glyceryl monoleate, lecithin, polysorbate 20 or 80) suspending agents/solvents (PEG), pH adjusting agents (acetic and citric acids, NaOH, HCI), mucoadhesive polymers (e.g., HPMC, chitosan), fillers/binders (e.g., cellulose-based polymers, maltodextrin, propylene glycol, colloidal silicon dioxide, guar gum) and flavors (e.g., menthol, saccharin sodium, sorbitol).
In an embodiment, the Rho/ROCK signaling pathway inhibitor or composition comprising same is used in combination another therapeutic agent. For example, the Rho/ROCK signaling pathway inhibitor or composition comprising same may be used with agents or therapies used in the treatment of CRS, such as topical intranasal steroids (e.g., prednisone, budenoside), oral antibiotics (e.g., fluoroquinolones, amoxicillin, amoxicillin¨clavulanate acid combinations), topical antibiotics, nasal saline irrigation, statins , probiotics, surgery (e.g., endoscopic sinus surgery), oral steroids or combination of oral antibiotics and steroids. The combination of agents may be G16612.00005 co-administered (e.g., consecutively, simultaneously, at different times). In an embodiment, the co-administration is coextensive, i.e. occurs during overlapping periods of time. In another embodiment, the Rho/ROCK signaling pathway inhibitor or composition comprising same and the other agent/therapy are administered consecutively. In an embodiment, the Rho/ROCK signaling 5 pathway inhibitor and the other active agent are formulated in the same composition. In another embodiment, the Rho/ROCK signaling pathway inhibitor and the other active agent are formulated in separate compositions. In another embodiment, the Rho/ROCK signaling pathway inhibitor and the other active agent are in different compositions, but these compositions are present together in the same kit or package. The kit or package can optionally include one or more containers, 10 saline solutions (e.g., to reconstitute lyophilized, spray-dried or freeze-dried compositions prior to administration), buffers, written instructions, reference to an internet site, or electronic instructions (e.g. on a support such as a CD-ROM, DVD, USB flash drive), and more particularly instructions for performing the methods and uses described herein, i.e. for treating CRS in a patient.
The subject/patient to be treated may be a child, an adult or an elderly. In an 15 embodiment, the subject/patient is an adult or an elderly.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention is illustrated in further details by the following non-limiting examples.
Example 1: Materials and Methods A total of 35 samples, composed of 19 cases of CRSwNP and 16 controls were included in this study. The demographic data for each group is presented in Table 1.
Table 1: Demographic data of patients whose samples were used at the present study.
Data are presented by frequency of events.
Data CRSwNP Control Age 51.0 9.5 50.3 18.1 Gender 10F/16M 8F/8M
Previous ESS 10/26 Asthma 6/26 0/16 Smoking 6/26 1/16 IgE 100 Ul/mL 5/26 ESS: endoscopic sinus surgery; AERD: aspirin-exacerbated respiratory disease;
IgE: immunoglobulin E
G16612.00005 Surgical sample collection, cell isolation and primary culture.
CRSwNP diagnosis was performed according to the 2004 AAO-HNS guidelines31, and patients underwent ESS following failure of medical treatment. Control patients underwent ESS
for cerebral spinal fluid leak or non-secreting pituitary adenomas. Exclusion criteria for both groups comprised immune deficiencies, neoplasia, ciliary dyskinesia, cystic fibrosis, and systemic immunosuppression. Tissues obtained during surgery at the level of anterior ethmoidal bulla (control) or the polyp itself (CRSwNP) were immediately collected for subsequent cell isolation and culture.
After recovery, pNECs were isolated following a standardized procedure32-35.
Briefly, collected samples were immediately rinsed and incubated overnight at 4 C in MEM (minimum essential medium) medium (Life Technologies Carlsbad, CA, USA) supplemented with 7.5%
NaHCO3(Sigma-Aldrich, Saint-Louis, MO, USA), 2 mM L-glutamine (Life Technologies), 10 mM
HEPES (Thermo Fisher Scientific, Waltham, MA, USA), 0.05 mg/mL gentamycin (Sandoz, Boucherville, QC, Canada), 50 U/mL penicillin-streptomycin, 0.25 pg/mL
Fungizone (Life Technologies), 0.1 % protease and 10 pg/mL DNase (Sigma-Aldrich).
After 18h, Fetal Bovine Serum was added to the solution to neutralize the protease-DNase activity, and pNECs were gently scraped off the remaining tissue.
Following removal of red blood cells by treatment with ACK lysis buffer (0.1 mM NH4CI, 10 pM KHCO3, 10 nM EDTA), the cell suspension was characterized by immunodetection of specific epithelial markers which indicated a mix of basal (CK13-positive), ciliated (p-tubulin-positive) and goblet (MUC5AC-positive) cells. This freshly isolated pNECs suspension was then seeded in T75 flasks coated with Purecol (Cedarlane Laboratory, Burlington, ON, Canada), and grown in CnT-17 to expend progenitor 0K13-positive basal cells, until confluency (CelInTec Advanced Cell Systems, Bern, Switzerland) medium, supplemented with 100U/mL penicillin and streptomycin.
pNECs were then detached by trypsin solution; 100 000 cells (second passage) were seeded into 24-well plastic plates (Corning, NY, USA), and cultured in CnT-17. At 80% confluency, the CnT-17 medium was replaced by a mix of 1:1 volume of BEGM (bronchial epithelial cell growth medium - Lonza CC4175, Basel, CH) and DMEM (Dulbecco's Modified Eagle's Medium - Thermo Fisher Scientific), supplemented with 1.5 pg/ml BSA, lx 10-7 M retinoic acid and 100 Wm: of penicillin-strept0mycin32-35.
S. aureus strains S. aureus (Rosenbach ATCC 25923 strain, Manassas, VA, USA) was cultured in Luria Bertani (LB, Difco, Montreal, QC, CA) agar, under agitation at 250 rpm at 37 C. Planktonic bacterial cultures at stationary phase after 24h of growth were centrifuged at 7,200 g for 10 min at room temperature. The supernatant was filtered with 0.22 vt.m cellulose acetate filters (Corning) G16612.00005 to remove bacteria, and filtrates, containing SA exoproducts, were aliquoted and stored at -80 C.
One aliquot of this filtrate was heated at 95 C for 15 minutes to inactivate protease activity (for comparison to non-heat inactivated aliquots). This aliquot was cooled after heating and stored for future assays.
Wound healing assay pNECs were injured mechanically (3 wounds / well, 3 wells / condition), using a well-established, highly reproducible technique2,34-37. After wounding, the cultures were washed to remove detached cells, and then randomly treated in either of the following conditions (performed in triplicate): 1) negative control: 0.5% (v/v) of LB, 2) exposure to SA
exoproducts, (at both concentrations of 0.25% and 0.5% (v/v) SA filtrate), and 3) exposure to SA
exoproducts (both concentrations of 0.25% and 0.5% (v/v) SA filtrate) and the ROCK inhibitor Y-dihydrochloride (5 p.M, Sigma-Aldrich ).
As a final assay, heat-inactivated-SA exoproducts were used, and the epithelial repair rates were reassessed, at the following conditions: 1) negative control: 0.5%
(v/v) of LB, 2) exposure to SA exoproducts (at concentration of 0.5% (v/v) SA filtrate) and 3) exposure to heat-inactivated SA exoproducts (concentration of 0.5% (v/v) SA filtrate).
A mark on wells allowed us to capture images of the wounds at exactly the same place at t=Oh and t=6h using an inverted microscope with a 4x objective (Nikon EclipseTM TE 2000).
Images were registered using AxioVision TM 4.8 software (Carl Zeiss, Jena, Germany) and then analyzed with Image J software (NIH, Bethesda, MD, USA) to measure areas at t=Oh and t=6h of wound healing and then to calculate the repair rates (expressed in 1.im2/h).
Analysis of Lamellipodial Dynamics by Kymograph Brightfield time-lapse series were made on pNECs from patients with CRSwNP and control subjects plated in 2-well silicone culture inserts (Ibidi #80209, Fitchburg, USA) using an inverted Axio ObserverZ1 microscope equipped with a CoolSNAPTM EZ CCD camera and a 10x/0.3 NA air objective lens, and then analyzed by AxioVision TM software.
Immediately prior to image acquisition, cells were treated with LB (control condition for SA) or LB + water (control condition for SA+Y-27632). Cells were then positioned into the incubation chamber (37 C, 5% CO2) and images were captured every minute for 2h to observe cell protrusions and retractions. Then, cells were treated with either SA
exoproducts (concentration of 0.5% (v/v)) or a mix of SA (concentration of 0.5% v/v) and Y-27632 (5 pM), with the recording pursued during the following 4h.
For each patient, on each time-lapse series, 4 to 6 cells exhibiting lamellipodia with consistent and dynamic protrusion/retraction cycles were randomly chosen for analysis. A one pixel-wide line crossing the cell membrane perpendicularly to the lamellipodia was drawn, and G16612.00005 this region was extracted from each image of the time-lapse series, as previously described by Choi et a/.38. Kymographs (time-space plots) were generated with the "Multiple Kymograph" plugin (J. Rietdorf, FMI Basel and A. Seitz, EMBL, Heidelberg, Germany) for ImageJ.
On kymographs, the x-axis represents time while the y-axis is the distance, where each protrusion/retraction cycle appears as a peak (FIG. 8). On each kymograph, segments following protrusions were manually retraced with the ImageJ segmented line tool. Data derived from these segmented lines were generated using "read velocity tsp macro" of ImageJ and used to calculate the length and velocity of each protrusion. At least a total of 40-110 individual protrusion events per condition and at least 14 different cells were analyzed in 3 independent time-lapse series.
lmmunofluorescence pNECs were grown to confluency on coverslips (precision cover glasses thickness No.
1.5H, Marienfeld, Lauda-Konigshofen, Germany) coated with PurecolTM. After injury, (3 mechanical wounds / coverslip), cell monolayers were washed and then treated with either: 1) LB
(concentration of 0.5% (v/v)): negative control, 2) SA exoproducts (concentration of 0.5% (v/v) SA
filtrate) and 3) SA exoproducts (concentration of 0.5% (v/v) SA filtrate) and Y-27632 (5p.M). After 4h of repair, cell monolayers were fixed with 4% paraformaldehyde in PBS for 5 min, permeabilized with 0.1% Triton TM X-100 in PBS for 10 min. After blocking (in 1% BSA in PBS for at least 1h at 4 C), fixed cells were incubated with the primary anti-p-tubulin antibody (1:1000 in PBS+BSA1%, Millipore, Etobicoke, Canada) for 1h at room temperature, and then with Alexa Fluor -488 conjugated goat anti-mouse antibody secondary antibody (1:2000 in PBS+BSA1%,1h, room temperature Thermo Fischer Scientific, Waltham, USA). F-actin was stained with Phalloidin-Alexa Fluor 594(1 unit, Thermo Fischer Scientific) (in PBS+BSA1%, for 1h at room temperature) and nuclei with DAPI (1:1000 in PBS+BSA1%, for 5 min). Coverslips were mounted with ProLong Gold Antifade Reagent (Molecular Probes, Eugene, USA) on SuperFrostTM glass slides (Thermo Fisher Scientific). Images were acquired with an inverted confocal microscope (TCS SP5, Leica Microsystems, Wetzlar, Germany) using an oil-immersion objective 63X/1.4. On immunofluorescence images, cells at the wound edge were classified according to the categories "with" or "without" lamellipodia as well as "ambiguous morphology" (see FIG.
10)39. Percentages of cells in each category were then calculated.
Statistical Analysis The data from all experiments are presented as mean SEM. ANOVA with Bonferroni post-hoc tests were used to compare the different conditions in the same group, and to compare the same condition between groups. Comparisons were considered statistically significant if p<0.05. In figures, statistical differences are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***) G16612.00005 or non-significant (NS), GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA) was used to analyze all results.
Example 2: Effect of SA on control and CRSwNP samples During the last years, sinonasal epithelium has been intrinsically imbricated to CRSwNP
physiopathology. Indeed, the epithelial barrier defense is determinant to maintain mucosal homeostasis, either due to its physical (avoiding the entrance of pathogens) and functional implication (defense against pathogens through the release of inflammatory and antimicrobial substances)40-43. To this end, the epithelium is a key inducer of both innate and adaptive inf1ammati0e-43. Very recently, Schleimer43 proposed that mucosal injury and repair may be a key process at CRSwNP: a prolonged loss of barrier function of the epithelium may facilitate the entrance of pathogens / inhalants, and thus facilitate chronic inflammation.
It was thus evaluated whether the ability of nasal epithelia to repair differed between CRSwNP and control samples under baseline culture conditions. For this purpose, pNECs from controls and CRSwNP were cultured in parallel, in the same conditions, and then wounded, to compare their repair rates. The 2D cultures are predominantly composed of basal progenitor cells, playing a critical role in epithelial repair through their ability to migrate into the injured area and then proliferate". Repair rate analysis (FIGs. 1A, 1B) in each pNECs cultures from control subjects and CRSwNP patients (CRSwNP) revealed a variability among individual within each group. However, the mean wound repair rates were significantly slower (p<0.001) in pNECs monolayers from CRSwNP than controls, under baseline conditions (LB) (FIG. 1B).
It was then assessed whether exposure to SA exoproducts could alter the wound healing capacity of pNECs epithelia. A significant decrease in the repair of control pNECs monolayers was observed in the presence of 0.25% SA exoproducts (FIG. 2A). A stronger inhibitory effect (p<0.001) was observed after exposure to SA exoproducts at 0.5% (41% decrease compare to the repair rates in LB condition). A dose dependent inhibition of wound repair was observed in CRSwNP monolayers (34% and 69% decrease in the presence of SA 0.25% (p<0.01 vs. LB) and SA 0.5% (p<0.01 vs. LB), respectively (FIG. 2B).
To determine which component could be responsible for this deleterious response, heat-inactivated SA 0.5% exoproducts (SAnactive) were used, and their effect on the epithelial repair of pNECs monolayers from CRSwNP patients was reassessed (FIG. 9). It was observed that the epithelial repair was only weakly influenced by heat-inactivated SA 0.5%
exoproducts (SAnactive VS. LB: 14% decrease, non-significant), in contrast to active SA 0.5%
exoproducts within the same pNECs cultures (LB vs. SA: 88% decrease, p<0.001; and SA vs. SA,: 86%
increase, p<0.001).
Epithelial repair is dependent on several mechanisms, one of them being the coordinated and directional cell migration45. To optimize this lively process, the actin filaments organize themselves in a dynamic network, and create a sheet-like membrane protrusion, known as G16612.00005 Lamellipodia formation and orientation was thus further evaluated using video kymograph analysis. It was first confirmed that LB per se had no effect on cell movement.
Kymographs of pNECs cultures for both controls and CRSwNP before and after exposure to SA
exoproducts were subsequently evaluated.
5 Control cells depicted a mean protrusion length and velocity of 10.5 1.36 pm and 1.62 0.24 pm/min, respectively, in LB conditions. Subsequent exposure to SA
exoproducts (SA
0-2h) induced a 57% (p<0.01) and 60% (p<0.05) decrease in protrusion length and velocity, respectively, followed by a partial recovery of these parameters during the final two hours of the study observation (SA 2-4h) (FIG. 3A, 3B). In CRSwNP cells, both protrusion length (6.23 0.99 10 pm) and velocity (0.78 0.11 pm/min) were altered at baseline (LB
condition) and the exposure to SA exoproducts significantly worsened the levels of protrusion length and velocity. Moreover, in contrast with control pNECs, the effect of SA was persistent throughout the entire period following exposure to SA exoproducts (SA 0-2h and SA 2-4h).
Finally, the cellular cytoskeleton organization was evaluated by immunofluorescence 15 experiments. Microtubules and actin microfilaments were stained with a specific 13-tubulin antibody and with fluorescent phalloidin, respectively. Under LB condition, it was observed that the leading cells at the wound edge of injured pNECs monolayers from control subjects exhibited more pronounced lamellipodial extensions (see cells marked with an asterisk, FIG. 4A, merge) than the pNECs cultured from CRSwNP samples. However, control and CRSwNP pNECs 20 appeared to be correctly polarized and oriented towards the injured area (FIG. 4A). There was no substantial difference in F-actin or 13-tubulin distribution within the control and CRSwNP
pNECs. However, further analysis and lamellipodial cell quantification at the wound edge showed distinct patterns for control and CRSwNP pNECs (FIG. 4B). Indeed, the percentage of cells with lamellipodia was significantly lower in epithelia from CRSwNP patients than in those from control subjects (Control: 60% vs. CRSwNP: 41%), whereas the percentage of cells without lamellipodia was higher (Control: 8% vs. CRSwNP: 20%) (FIG. 4B).
Both control and CRSwNP pNECs were altered after exposure to SA exoproducts, exhibiting a more rounded shape, suggesting a loss in cell polarization, and a reorganization of the microtubule cytoskeleton, with an increase in microtubules localized circularly under the .. plasma membrane (FIG. 4A). Additionally, lamellipodial cell quantification showed that SA
exoproduct exposure induced significant decreases in the percentage of cells with lamellipodia at the wound edge (Control subjects: LB: 60% vs. SA: 25%; CRSwNP patients: LB:
41% vs. SA:
10%) (FIG. 4B). Conversely, the percentage of cells without lamellipodia is significantly increased after SA exoproduct exposure in epithelia from control subjects (LB: 8% vs.
SA: 34%) and CRSwNP patients (LB: 20% vs. SA: 45%) (FIG. 4B).
Example 3: Effect of ROCK inhibition on epithelial repair in pNECs G16612.00005 The effect of a potent Rho kinase (ROCK) inhibitor, Y-27632, on epithelial repair in pNECs exposed to SA exoproducts was assessed. It was first determined, in a pilot study, that 5 IV1 was the optimal dose for Y-27632 in pNEC. Indeed, treatment with 5 [INA of Y-27632, in LB
condition, led to an increase in epithelial repair rate of 23%, while increasing concentrations altered migration and induced pNECs apoptosis pNECs monolayers were then exposed to SA exoproducts either in the presence or absence of Y-27632 (5 M) (FIG. 5). The drug inhibited the deleterious effect of SA, increasing significantly the repair rates by almost 2-fold (1.86-fold) when co-cultured with SA 0.25%, and by 2.22-fold with SA 0.5%, compared to corresponding SA conditions in the absence of Y-27632.
It was also assessed whether the beneficial effect of Y-27632 on epithelial repair in the presence of SA exoproducts was related to an improvement in lamellipodial dynamics and migration. Whereas both protrusion length and velocity in CRSwNP pNECs were altered by the exposure to SA exoproducts (FIG. 3), this deleterious effect was no longer observed (FIG. 6) when CRSwNP pNECs were exposed simultaneously to SA 0.5% and Y-27632. Indeed, the length and the velocity of protrusions measured after treatments with SA+Y
were similar to those observed in the absence of SA (FIG. 6, LB vs. SA+Y). Finally, the cellular cytoskeleton organization after exposure to SA, in the absence and presence of Y-27632, was compared. It was first confirmed that, in the absence of Y-27632, SA exposure induced the cells to adopt a rounded shape, with lamellipodial extension substantially compromised at the leading edge of injury (FIG. 7A). Treatment with Y-27632 partially restored lamellipodial extensions: although the extension was not as prominent as under baseline conditions, most of the cells at the leading edge presented a more elongated shape and exhibited the lamellipodia pattern directed towards the injured area (FIG. 7A, see cells marked with an asterisk at the leading edge in LB and SA+Y
conditions). Interestingly, lamellipodial cell quantification showed that, after exposure to SA
exoproduct combined with the Y-27632 compound, injured epithelia from CRSwNP
patients exhibited significantly more cells with lamellipodia (SA: 13% vs. SA+Y: 65%) and significantly less cells without lamellipodia (SA: 43% vs. SA+Y: 8%) (FIG. 7B), confirming that ROCK inhibition improves lamellipodial dynamics and migration.
Although the present invention has been described hereinabove by way of specific embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The singular forms "a", "an" and "the" include corresponding plural references unless the context clearly dictates otherwise.
G16612.00005 REFERENCES
1. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al.
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol.
2016;6:S22-209. DOI: 10.1002/alr.21695.
2. DeConde AS, Soler ZM. Chronic rhinosinusitis: Epidemiology and burden of disease. Am J
Rhino! Allergy. 2016;30:134-9. DOI: 10.250/ajra.2016.30.4297.
3. Soler ZM, Wittenberg E, Schlosser RJ, MacE JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121:2672-8.
DOI:
10.1002/lary.21847.
4. Erskine S, Hopkins C, Kumar N, Wilson J, Clark A, Robertson A, et al. A
cross sectional analysis of a case-control study about quality of life in CRS in the UK; a comparison between CRS subtypes. Rhinology. 2016;54:311-5. DOI: 10.4193/Rhino15.361.
5. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope.
2017;127(3):550-5. DOI: 10.1002/lary.26391 6. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the english national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis.
Laryngoscope. 2009;119:2459-65. DOI: 10.1002/lary.20653 7. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al.
Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN-y and IL-4.
J Allergy Clin Immunol. 2012;130:1087-96. DOI: 10.1016/j.jaci.2012.05.052.
8. Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al.
Oncostatin M
promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015; 136:737-46.
DOI:
10.1016/j.jaci.2015.01.043.
9. Loxham M, Davies DE. Phenotypic and genetic aspects of epithelial barrier function in asthmatic patients. J Allergy Clin Immunol.
2017;139:1736-51. DOI:
10.1016/j.jaci.2017.04.005.
10. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014;134:509-20. DOI:
10.1016/j.jaci.2014.05.049.
11. Yu XM, Li CW, Chao SS, Li YY, Yan Y, Zhao XN, et al. Reduced growth and proliferation dynamics of nasal epithelial stem/progenitor cells in nasal polyps in vitro.
Sci Rep.
2014;4:4619. DOI: 10.1038/srep04619.
12. Yu XM, Li CW, Li YY, Liu J, Lin Z Bin, Li TY, et al. Down-regulation of EMP1 is associated with epithelial hyperplasia and metaplasia in nasal polyps. Histopathology.
2013;63:686-95.
G16612.00005 DOI: 10.1111/his.12211.
13. Bosse Y, Bacot F, Montpetit A, Rung J, Qu HQ, Engert JC, et al.
Identification of susceptibility genes for complex diseases using pooling-based genome-wide association scans.
Hum Genet. 2009;125:305-18. DOI 10.1007/s00439-009-0626-9.
14. Thanasumpun T, Batra PS. Endoscopically-derived bacterial cultures in chronic rhinosinusitis: A systematic review. Am J Otolaryngol - Head Neck Med Surg.
2015;36:686-91. DOI: 10.1016/j.amjoto.2015.04.010 15. Zhang Z, Adappa ND, Doghramji LJ, Chiu AG, Cohen NA, Palmer JN. Different clinical factors associated with Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015;5:724-33. DOI:
10.1002/alr.21532 16. Corriveau MN, Zhang N, Holtappels G, Van Roy N, Bachert C. Detection of Staphylococcus aureus in nasal tissue with peptide nucleic acid-fluorescence in situ hybridization. Am J
Rhinol Allergy. 2009;23:461-5. DOI: 10.2500/ajra.2009.23.3367.
17. Tan NCW, Foreman A, Jardeleza C, Douglas R, Vreugde S, Wormald PJ.
Intracellular Staphylococcus aureus: The Trojan horse of recalcitrant chronic rhinosinusitis? Int Forum Allergy Rhinol. 2013;3:261-6. DOI: 10.1002/alr.21154.
18. Kim RJT, Yin T, Chen CJJ, Mansell CJ, Wood A, Dunbar PR, et al. The interaction between bacteria and mucosal immunity in chronic rhinosinusitis: A prospective cross-sectional analysis. Am J Rhinol Allergy. 2013;27:183-90. DOI: 10.2500/ajra.2013.27.3974.
19. Tan NCW, Cooksley CM, Roscioli E, Drilling AJ, Douglas R, Wormald PJ, et al. Small-colony variants and phenotype switching of intracellular Staphylococcus aureus in chronic rhinosinusitis. Allergy. 2014;69:1364-71. D01:10.1111/a11.12457.
20. Kohanski MA, Lane AP. Sinonasal epithelial cell response to Staphylococcus aureus burden in chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2015;141:341-9.
DOI:
10.1001/jamaoto.2014.3550.
21. Gevaert E, Zhang N, Krysko 0, Lan F, Holtappels GE, De Ruyck N, et al.
Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol.
2017;139:1849-60. DOI: 10.1016/j.jaci.2017.01.019.
22. Teufelberger AR, Nordengrun M, Braun H, Maes T, De Grove K, Holtappels G, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by the Staphylococcus aureus protease SpID. J Allergy Clin lmmunol. 2017; Epub Ahead. DOI:
10.1016/j.jaci.2017.05.004.
23. Malik Z, Roscioli E, Murphy J, Ou J, Bassiouni A, Wormald PJ, et al.
Staphylococcus aureus impairs the airway epithelial barrier in vitro. Int Forum Allergy Rhinol.
2015;5:551-6. DOI:
10.1002/alr.21517.
24. Seop Kim C, Jeon S-Y, Min Y-G, Rhyoo C, Kim J-W, Bock Yun J, et al.
Effects of 13-Toxin of Staphylococcus aureus on Ciliary Activity of Nasal Epithelial Cells.
Laryngoscope.
G16612.00005 2000;110:2085-8.
25. Eiffler I, Behnke J, Ziesemer S, Muller C, Hildebrandt J-P. Staphylococcus aureus a-toxin-mediated cation entry depolarizes membrane potential and activates p38 MAP
kinase in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016;311:L676-85.
DOI:
10.1152/ajplung.00090.2016.
26. Hermann I, Rath S, Ziesemer S, Volksdorf T, Dress RJ, Gutjahr M, et al.
Staphylococcus aureus hemolysin A disrupts cell-matrix adhesions in human airway epithelial cells. Am J
Respir Cell Mol Biol. 2015;52:14-24. DOI: 10.1165/rcmb.2014-00820C.
27. Yin J, Yu F-SX. Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol. 2008;295:378-87. D01:10.1152/ajpce11.90624.2007.
28. Elamin E, Masclee A, Dekker J, Jonkers D. Ethanol disrupts intestinal epithelial tight junction integrity through intracellular calcium-mediated Rho/ROCK activation. Am J
Physiol Gastrointest Liver Physiol. 2014;306:G677-85. 001: 10.1152/ajpgi.00236.2013.
29. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J
Physiol Lung Cell Mol Physiol. 2010;298: L715-31. DOI: 10.1152/ajplung.00361.2009.
30. Sun CC, Chiu HT, Lin YE, Lee KY, Pang JHS. Y-27632, a ROCK inhibitor, promoted limbal epithelial cell proliferation and corneal wound healing. PLoS One. 2015;10:1-18.
D01:10.1371/journal.pone.0144571.
31. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BE, Nicklas RA, et al.
Rhinosinusitis:
Establishing definitions for clinical research and patient care. J Allergy Clin Immunol.
2004;114:5155-212. D01:10.1016/j.jaci.2004.09.029.
32. Ruffin M, Bilodeau C, Maille E, LaFayette SL, McKay GA, Trinh NTN, et al.
Quorum-sensing inhibition abrogates the deleterious impact of Pseudomonas aeruginosa on airway epithelial repair. FASEB J. 2016;30:3011-25. DOI: 10.1096/fj.201500166R.
33. Trinh NT, Bilodeau C, Male E, Ruffin M, Quintal M, Desrosiers M, et al.
Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur Respir J. 2015;45:1590-602. DOI:
10.1183/09031936.00076214 34. Trinh N, Bardou 0, Prive A, Maine E, Adam D, Lingee S, Ferraro P, Desrosiers M, Coraux C
BE. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR
rescue. Eur Respir J. 2012;40:1390-400. DOI: 10.1183/09031936.00221711.
35. Bilodeau C, Bardou 0, Male E, Berthiaume Y, Brochiero E. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J
Cyst Fibros.
2016;15:43-51. DOI: 10.1016/j.jcf.2015.04.002.
36. Maine E, Trinh NTN, Prive A, Bilodeau C, Bissonnette E, Grandvaux N, et al. Regulation of normal and cystic fibrosis airway epithelial repair processes by TNF-a after injury. Am J
Physiol Lung Cell Mol Physiol. 2011;301:L945-55. DOI:
10.1152/ajplung.00149.2011.
G16612.00005 37. Trinh NTN, Prive A, MaiIle E, Noel J, Brochiero E. EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. Am J Physiol Lung Cell Mol Physiol.
2008;295:L866-80. DOI: 10.1152/ajplung.90224.2008.
38. Choi S, Camp SM, Dan A, Garcia JG, Dudek SM, Leckband DE. A genetic variant of cortactin linked to acute lung injury impair lamellipodia dynamics and endothelial wound healing. Am J Physiol Lung Cell Mol Physiol. 2015;3091983-94. DOI:
10.1152/ajplung.00062.2015.
39. Steffen A, Rottner K, Ehinger J, Innocenti M, Scita G, Wehland J, et al.
Sra-1 and Nap1 link Rac to actin assembly driving lamellipodia formation. EMBO J. 2004;23:749-59.
40. Zhang N, van Crombruggen K, Gevaert E, Bachert C. Barrier function of the nasal mucosa in health and type-2 biased airway diseases. Allergy. 2016;71:295-307. DOI:
10.1111/a11.12809.
41. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF.
Endotype-driven treatment in chronic upper airways diseases. Clin Trans Allergy. 2017;7-22.
DOI:
10.1186/s13601-017-0157-8.
42. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J
Allergy Olin Immunol. 2015;136:1142-53. DOI: 10.1016/j.jaci.2015.10.009.
43. Schleimer RP. lmmunopathogenesis of chronic rhinosinusitis and nasal polyps. Annu Rev Pathol Mech Dis. 2017;12:331-57. DOI: 10.1146/annurev-pathol-052016-100401.
44. Duan C, Li OW, Zhao L, Subramaniam S, Yu XM, Li YY, et al. Differential expression patterns of egf, egfr, and erbb4 in nasal polyp epithelium. PLoS One. 2016;11:1-14.
DOI:
10.1371/journal.pone.0156949.
45. Desai LP. RhoA and Rac1 are both required for efficient wound closure of airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1134-44. DOI:
10.1152/ajplung.00022.2004.
46. de Bentzmann S, Polette M, Zahm J, Hinnrasky J, Kileztky C, Bajolet 0, et al. Pseudomonas Aeruginosa Virulence Factors Delay Airway Epithelial Wound Repair by Altering the Actin Cytoskeleton and Inducing Overactivation of Epithelial Matrix Metalloproteinase-2. Lab Invest. 2000;80:209-19.
47. Menko AS, Bleaken BM, Walker JL. Regional-specific alterations in cell-cell junctions, cytoskeletal networks and myosin-mediated mechanical cues coordinate collectivity of movement of epithelial cells in response to injury. Exp Cell Res. 2014;322:133-48. DOI:
10.1016/j.yexcr.2013.12.021.
48. Horani A, Nath A, Wasserman MG, Huang T, Brody SL. Rho-associated protein kinase inhibition enhances airway epithelial basal-cell proliferation and lentivirus transduction. Am J
Respir Cell Mol Biol. 2013;49:341-7. DOI: 10.1165/rcmb.2013-0046TE.
49. Moore M, Marroquin BA, Gugliotta W, Tse R, White SR. Rho Kinase Inhibition Initiates Apoptosis in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol.
2004;30:379-87. DOI:
G16612.00005 10.1165/rcmb.2003-00190C.
50. Zuo W, Zhang T, Wu DZ, Guan SP, Liew A-A, Yamamoto Y, et al.
p63+Krt5+ distal airway stem cells are essential for lung regeneration. Nature. 2014;517:616-20. DOI:
10.1038/nature13903.
51. Arason AJ, Jonsdottir HR, Halldorsson S, Benediktsdottir BE, Bergthorsson JT, Ingthorsson S, et al. DeltaNp63 has a role in maintaining epithelial integrity in airway epithelium. PLoS
One. 2014;9:e88683. 001:10.1371/journal.pone.0088683.
52. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J
Physiol Lung Cell Mol Physiol. 2010;298:L715-31. DOI: 10.1152/ajplung.00361.2009.
53. Marano RJ, Wallace HJ, Wijeratne D, Fear MW, Wong HS, O'Handley R.
Secreted biofilm factors adversely affect cellular wound healing responses in vitro. Sci Rep.
2015;5:13296.
D01:10.1038/srep13296 54. Brothers KM, Stella NA, Hunt KM, Romanowski EG, Liu X, Klarlund JK, et al.
Putting on the brakes: Bacterial impediment of wound healing. Sci Rep. 2015;5:14003 I DOI:
10.1038/srep14003.
55. Wise SK, Den Beste KA, Hoddeson EK, Parkos CA, Nusrat A. Sinonasal epithelial wound resealing in an in vitro model: Inhibition of wound closure with IL-4 exposure. Int Forum Allergy Rhinol. 2013;3:439-49. DOI: 10.1002/alr.21158.
56. Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson 0, et al. Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother. 2015;59:299-309. D01:10.1128 /AAC.03918-14.
57. Ljubimov A V., Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res.
2015;49:17-45D01: 10.1016/j.preteyeres.2015.07.002.
2015;49:17-45D01: 10.1016/j.preteyeres.2015.07.002.
58. Mfuna-Endam L, Zhang Y, Desrosiers MY. Genetics of rhinosinusitis. Curr Allergy Asthma Rep. 2011;11:236-46. DOI: 10.1007/s11882-011-0189-4.
59. lorio V, Troughton LD, Hamill KJ. Laminins: Roles and Utility in Wound Repair. Adv Wound Care. 2015;4:250-63. DOI: 10.1089/wound.2014.0533.
60. Purkey MT, Li J, Mentch F, Grant SF, Desrosiers M, Hakonarson H, et al.
Genetic variation in genes encoding airway epithelial potassium channels is associated with chronic rhinosinusitis in a pediatric population. PLoS
One. 2014;9:e89329.
DOI: 10.1371/journal.pone.0089329.
Genetic variation in genes encoding airway epithelial potassium channels is associated with chronic rhinosinusitis in a pediatric population. PLoS
One. 2014;9:e89329.
DOI: 10.1371/journal.pone.0089329.
61. Girault A, Chebli J, Prive A, Trinh NTN, Maine E, Grygorczyk R, et al.
Complementary roles of KCa3.1 channels and p1-integrin during alveolar epithelial repair. Respir Res.
2015;16:100. DOI 10.1186/s12931-015-0263-x.
Complementary roles of KCa3.1 channels and p1-integrin during alveolar epithelial repair. Respir Res.
2015;16:100. DOI 10.1186/s12931-015-0263-x.
62. Girault A, Brochiero E. Evidence of K+ channel function in epithelial cell migration, proliferation, and repair. Am J Physiol Cell Physiol. 2014;306:C307-19. DOI:
G16612.00005 10.1152/ajpce11.00226.2013.
G16612.00005 10.1152/ajpce11.00226.2013.
63. Cormier C, Mfuna Endam L, Filali-Mouhim A, Boisvert P, Boulet L-P, Boulay M-E, et al. A
pooling-based genomewide association study identifies genetic variants associated with Staphylococcus aureus colonization in chronic rhinosinusitis patients. Int Forum Allergy Rhinol. 2014;4:207-15. DOI: 10.1002/alr.21276.
pooling-based genomewide association study identifies genetic variants associated with Staphylococcus aureus colonization in chronic rhinosinusitis patients. Int Forum Allergy Rhinol. 2014;4:207-15. DOI: 10.1002/alr.21276.
64. Saint-Criq V, Villeret B, Bastaert F, Kheir S Hatton A, Cazes A, et al.
Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway. Thorax.
2017;Epub Ahead. DOI: 10.1136/thoraxjnI-2017-210298.
.. 65. Popoff MR. Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host. Small GTPases. 2014;5:e28209.
doi:
10.4161/sgtp.28209.
66. Boyer L, Doye A, Rolando M, Flatau G, Munro P, Gougon P et al. Induction of transient macroapertures in endothelial cells through RhoA inhibition by Staphylococcus aureus factors. J Cell Biol. 2006;173:809-19.
67. Dach K, Zovko J, Hogardt M, Koch I, van Erp K, Heesemann J, et al.
Bacterial toxins induce sustained mRNA expression of the silencing transcription factor k1f2 via inactivation of RhoA
and Rhophilin 1. Infect lmmun. 2009;77:5583-92. DOI: 10.1128/IA1.00121-09.
68. Soong G, Martin FJ, Chun J, Cohen TS, Ahn DS, Prince A. Staphylococcus aureus protein A mediates invasion across airway epithelial cells through activation of RhoA
GTPase signaling and proteolytic activity. J Biol Chem. 2011;286:35891-8. DOI:
10.1074/jbc.M111.295386.
69. Narimatsu T, Ozawa Y, Miyake S, Kubota S, Hirasawa M, Nagai N, et al.
Disruption of cell-cell junctions and induction of pathological cytokines in the retinal pigment epithelium of light-exposed mice. Invest Ophthalmol Vis Sci. 2013;54:4555-62. D01:10.1167/ iovs.12-11572.
Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway. Thorax.
2017;Epub Ahead. DOI: 10.1136/thoraxjnI-2017-210298.
.. 65. Popoff MR. Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host. Small GTPases. 2014;5:e28209.
doi:
10.4161/sgtp.28209.
66. Boyer L, Doye A, Rolando M, Flatau G, Munro P, Gougon P et al. Induction of transient macroapertures in endothelial cells through RhoA inhibition by Staphylococcus aureus factors. J Cell Biol. 2006;173:809-19.
67. Dach K, Zovko J, Hogardt M, Koch I, van Erp K, Heesemann J, et al.
Bacterial toxins induce sustained mRNA expression of the silencing transcription factor k1f2 via inactivation of RhoA
and Rhophilin 1. Infect lmmun. 2009;77:5583-92. DOI: 10.1128/IA1.00121-09.
68. Soong G, Martin FJ, Chun J, Cohen TS, Ahn DS, Prince A. Staphylococcus aureus protein A mediates invasion across airway epithelial cells through activation of RhoA
GTPase signaling and proteolytic activity. J Biol Chem. 2011;286:35891-8. DOI:
10.1074/jbc.M111.295386.
69. Narimatsu T, Ozawa Y, Miyake S, Kubota S, Hirasawa M, Nagai N, et al.
Disruption of cell-cell junctions and induction of pathological cytokines in the retinal pigment epithelium of light-exposed mice. Invest Ophthalmol Vis Sci. 2013;54:4555-62. D01:10.1167/ iovs.12-11572.
Claims (37)
1. Use of a Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
2. Use of a Rho/ROCK signaling pathway inhibitor for the manufacture of a medicament for promoting sinonasal epithelial cell repair in a subject
3. The use of claim 1 or 2, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
4. The use of claim 1, wherein the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 and/or ROCK2 and blocks its activity.
5. The use of claim 1, wherein the ROCK inhibitor is an antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 and/or human ROCK2.
6. The use of claim 1, wherein the ROCK inhibitor is Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S 7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
7. The use of claim 6, wherein the ROCK inhibitor is Y-27632 or a pharmaceutically acceptable salt thereof.
8. The use of claim 7, wherein the ROCK inhibitor is a dihydrochloride salt of Y-27632.
9. The use of any one of claims 1 to 8, wherein the subject suffers from rhinosinusitis.
10. The use of claim 9, wherein the subject suffers from chronic rhinosinusitis (CRS).
11. The use of claim 10, wherein the subject suffers from CRS with nasal polyps (CRSwNP).
12. The use of any one of claims 9 to 11, wherein the subject underwent endoscopic sinus surgery (ESS) prior to said use.
13. The use of any one of claims 9 to 12, wherein the rhinosinusitis is associated with a bacterial infection.
14. The use of claim 13, wherein the bacterial infection comprises Staphylococcus aureus infection.
15. The use of any one of claims 1 to 14, wherein the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition with at least one pharmaceutically acceptable carrier or excipient.
16. The use of any one of claims 1 to 15, wherein the Rho/ROCK signaling pathway inhibitor is for intranasal administration.
17. The use of claim 16, wherein the Rho/ROCK signaling pathway inhibitor is coated on a nasal or sinus implant.
18. The use of any one of claims 1 to 17, wherein the Rho/ROCK signaling pathway inhibitor is used in combination with at least one additional active agent.
19. The use of claim 18, wherein the at least one additional active agent comprises a steroid and/or an antibiotic.
20. A Rho/ROCK signaling pathway inhibitor for promoting sinonasal epithelial cell repair in a subject.
21. The Rho/ROCK signaling pathway inhibitor for use according to claim 20, wherein the Rho/ROCK signaling pathway inhibitor is a Rho kinase (ROCK) inhibitor.
22. The Rho/ROCK signaling pathway inhibitor for use according to claim 21, wherein the ROCK inhibitor is an antibody or an antigen-binding fragment thereof that binds to ROCK1 and/or ROCK2 and blocks its activity.
23. The Rho/ROCK signaling pathway inhibitor for use according to claim 21, wherein the ROCK inhibitor is an antisense compound specifically hybridizes with a nucleic acid encoding human ROCK1 and/or human ROCK2.
24. The Rho/ROCK signaling pathway inhibitor for use according to claim 23, wherein the ROCK inhibitor is Fasudil (HA-1077), Hydroxyfasudil, Netarsudil, Ripasudil, RKI-1447, GSK429286A, GSK180736A, GSK269962A, Thiazovivin, AT13148, H1152, Glycyl-H1152, TC-S
7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
7001, AS-1892802, HA-1100, OXA-06, SB-772077B, SR-3677, KD025 (SLx-2119), Y-30141, Y-39983, ZINC00881524 or Y-27632, or a pharmaceutically acceptable salt thereof.
25. The Rho/ROCK signaling pathway inhibitor for use according to claim 24, wherein the ROCK inhibitor is Y-27632 or a pharmaceutically acceptable salt thereof.
26. The Rho/ROCK signaling pathway inhibitor for use according to claim 25, wherein the ROCK inhibitor is a dihydrochloride salt of Y-27632.
27. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 20 to 26, wherein the subject suffers from rhinosinusitis.
28. The Rho/ROCK signaling pathway inhibitor for use according to claim 27, wherein the subject suffers from chronic rhinosinusitis (CRS).
29. The Rho/ROCK signaling pathway inhibitor for use according to claim 28, wherein the subject suffers from CRS with nasal polyps (CRSwNP).
30. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 27 to 29, wherein the subject underwent endoscopic sinus surgery (ESS) prior to said use.
31. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 27 to 30, wherein the rhinosinusitis is associated with a bacterial infection.
32. The Rho/ROCK signaling pathway inhibitor for use according to claim 31, wherein the bacterial infection comprises Staphylococcus aureus infection.
33. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 20 to 32, wherein the Rho/ROCK signaling pathway inhibitor is formulated in a pharmaceutical composition with at least one pharmaceutically acceptable carrier or excipient.
34. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 20 to 33, wherein the Rho/ROCK signaling pathway inhibitor is for intranasal administration.
35. The Rho/ROCK signaling pathway inhibitor for use according to claim 34, wherein the Rho/ROCK signaling pathway inhibitor is coated on a nasal or sinus implant.
36. The Rho/ROCK signaling pathway inhibitor for use according to any one of claims 20 to 35, wherein the Rho/ROCK signaling pathway inhibitor is used in combination with at least one additional active agent.
37. The Rho/ROCK signaling pathway inhibitor for use according to claim 36, wherein the at least one additional active agent comprises a steroid and/or an antibiotic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/589,775 US20200101056A1 (en) | 2018-10-02 | 2019-10-01 | Use of rock inhibitors for promoting sinonasal epithelial cell repair |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739985P | 2018-10-02 | 2018-10-02 | |
US62/739,985 | 2018-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3046915A1 true CA3046915A1 (en) | 2020-04-02 |
Family
ID=70050291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3046915A Abandoned CA3046915A1 (en) | 2018-10-02 | 2019-06-17 | Use of rock inhibitors for promoting sinonasal epithelial cell repair |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3046915A1 (en) |
-
2019
- 2019-06-17 CA CA3046915A patent/CA3046915A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Valera et al. | Staphylococcus aureus impairs sinonasal epithelial repair: effects in patients with chronic rhinosinusitis with nasal polyps and control subjects | |
US20200101056A1 (en) | Use of rock inhibitors for promoting sinonasal epithelial cell repair | |
Steelant et al. | Histamine and T helper cytokine–driven epithelial barrier dysfunction in allergic rhinitis | |
ES2846789T3 (en) | Compositions containing HC-HA / PTX3 complexes and methods of using them | |
ES2704657T3 (en) | Selective targeting of the CD40L / MAC-1 interaction by small peptide inhibitors and their use for the treatment of inflammation and atherogenesis | |
Xiao et al. | Anti-fibrosis activity of quercetin attenuates rabbit tracheal stenosis via the TGF-β/AKT/mTOR signaling pathway | |
US10208308B2 (en) | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | |
ES2759226T3 (en) | Treatment of disorders of the central nervous system by intranasal administration of immunoglobulin G | |
Li et al. | Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization | |
KR20200115547A (en) | How to treat fibrotic pathology | |
AU2021261241A1 (en) | Methods and materials for treatment of fibrosis | |
Berair et al. | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma | |
Lan et al. | Forkhead domain inhibitory-6 attenuates subconjunctival fibrosis in rabbit model with trabeculectomy | |
CA3046915A1 (en) | Use of rock inhibitors for promoting sinonasal epithelial cell repair | |
US11466054B2 (en) | Inhibitors of metastasis | |
PT2262833E (en) | Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions | |
Huang et al. | AZD6738 decreases intraocular pressure and inhibits fibrotic response in trabecular meshwork through CHK1/P53 pathway | |
ES2957464T3 (en) | Compositions and methods for treating pulmonary fibrosis | |
Lee et al. | Inhibitory effect of tranilast on transforming growth factor-beta-induced protein in granular corneal dystrophy type 2 corneal fibroblasts | |
JP6975535B2 (en) | Drug delivery enhancer | |
ES2869909T3 (en) | Compositions and Methods for Surfactant Protein A Receptor Modification | |
González-Ortega et al. | Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor | |
JP2018507847A (en) | Prevention of secondary infection | |
US20140170158A1 (en) | Compositions and methods for treating or preventing lung diseases | |
CA3153932A1 (en) | Modulating lymphatic vessels in neurological disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20221219 |
|
FZDE | Discontinued |
Effective date: 20221219 |